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Zusammenfassung 
 
Hintergrund:  
MammaPrint® ist ein Test zur Ermittlung des Rezidivrisikos nach primärem 
Brustkrebs. Dieser sog. "Genexpressionstest" basiert auf der Analyse der Ak-
tivität von 70 Genen im Brusttumorgewebe. Der Test soll zusätzlich zur etab-
lierten klinisch-pathologischen Risikoabschätzung – in Abhängigkeit zum Ri-
sikobefund (niedrig/ hoch) – als Entscheidungshilfe für oder gegen eine ad-
juvante systemische Chemotherapie dienen. Der Anspruch dieses Tests ist 
es, dass einige PatientInnen auf der Basis von MammaPrint® von einer ad-
juvanten Chemotherapie absehen können und daher die damit verbundenen 
Nebenwirkungen wie Übelkeit und Erbrechen, Müdigkeit und Haarausfall, 
aber auch langfristige Nebenwirkungen nicht erleiden müssen.  
MammaPrint® wurde in klinischen Studien an PatientInnen mit Tumoren 
<5 cm (T1, T2, oder operabel T3)  bis max 3 befallenen Lymphknoten (N0-
1) unabhängig vom Östrogenrezeptor (ER) oder vom „human epidermal 
growth factor“ 2 (HER2) Rezeptor Status validiert. MammaPrint® wird von 
Agendia (Niederlande: http://www.agendia.com) vertrieben.  
 
Methode:  
Systematische Suche in mehreren Datenbanken nach randomsierten klini-
schen Studien zu MammaPrint®. Zur Beurteilung der internen Validität 
wurde das Cochrane Risk of Bias (RoB) Tool verwendet. Die Qualität der 
Evidenz wurde für jeden Endpunkt mit der GRADE-Methode (Grading of 
Recommendations, Assessment, Development and Evaluation) durchgeführt. 
 
Ergebnisse: 
Es konnte ein RCT identifiziert werden: die im August 2016 veröffentlichte 
MINDACT Studie. Diese open-label, randomisiert-kontrollierte Phase 3 Stu-
die wurde mit Frauen mit primärem Brustkrebs (n=6.693, medianes follow-
up 5 Jahre) durchgeführt.  Ziel von MINDACT war es, den klinischen Zusatz-
nutzen von MammaPrint® zusätzlich zur klinisch-pathologischen Risikoab-
schätzung (AO!) gegenüber dieser etablierten Methode allein zu belegen. 
MINDACT fokussierte auf  „diskordante Gruppen“, also jene Subgruppen mit 
klinisch-hohem, aber genomisch-niedrigem Risikoprofil (CH/ GL) resp. kli-
nisch-niedrigem und genomisch-hohem Risikoprofil (CL/GH).  Der Nutzen 
von MammaPrint® war definiert als zuverlässiger (sicherer) Verzicht von 
Chemotherapie in der CH/GL Subgruppe ohne Auswirkungen auf das Fern-
metastasen-freie Überleben (DMFS). Die Nicht-Unterlegenheitsgrenze wur-
de vorweg definiert als ein max 3% Risikounterschied zwischen den beiden 
Vergleichsgruppen. 
MammaPrint® = 
Genexpressionstest zur 
Ermittlung des 
Rezidivrisikos und zur 
Entscheidungshilfe für 
oder gegen eine 
adjuvante systemische 
Chemotherapie 
 
Ziel: Verzicht auf 
Chemotherapie 
systematischer Review 
RoB: Cochrane 
GRADE  
1 RCT = MINDACT 
6.693 Pts, 5 J FU 
primärer Brustkrebs 
 
AO! + MammaPrint® 
vs. AO!  
 
Fokus: diskordante 
Subgruppen 
 
Nicht-
Unterlegenheitsstudie  
definiert als  ≤ 3% 
Unterschied 
Ergebnisse in der CH/GL Population (n=542 vs. 503) (Überprüfung der non-
inferiority in der Per Protocol (PP) Population und superiority bei Lebens-
qualität (QoL) und Toxizität in intention-to-treat (ITT) Analyse):  In der PP-
Analyse betrug der Risikounterschied MammaPrint®+ AO! vs. AO!  allein 
b 2,5% bei 5-Jahres DMFS 96,5% (95% CI 94,1-97,9) mit Chemothera-
pie vs. 94,0% (95% CI 91,4-95,8) ohne Chemotherapie (HR=0,60; 
95% CI 0,34-1,06; p=0.080; nicht statistisch signifikant) – zuunguns-
ten von MammaPrint®,  
b 4,5% bei 5-Jahres DFS 93,0%  (95% CI 90,3-95,4) mit Chemotherapie 
vs. 88,8% (95% CI 85,7-91,3) ohne Chemotherapie (HR=0,57; 95% CI 
0,37-0,87; p=0.01: statistisch signifikant) – zuungunsten von 
MammaPrint®,   
b 1,8% bei 5-Jahres OS 98,8% (95% CI 97,1-99,5) mit Chemotherapie 
vs. 97,0% (95% CI 94,9-98,2) (HR=0,54; 95% CI 0,23-1,26; p=0.15; 
nicht statistisch signifikant) – zuungunsten von MammaPrint®. 
Die 95% CIs der HR (bei sehr breiten Konfidenzintervallen) von 5-Jahres 
DMFS und bei 5-Jahres OS zeigten non-inferiority (Schwellwert HR 0.80, 
non-inferiority von 3% Unterschied), nicht aber die point estimates. Daher 
kann angenommen werden, dass bei Verzicht auf Chemotherapie basierend 
auf MammaPrint® ein erhöhtes Risiko auf Fernmetastasen und Tod im Ver-
gleich zur AO!-Risikoabschätzung besteht. Obwohl MINDACT nicht ausrei-
chend gepowered war, um statistisch signifikante Unterschiede zu zeigen, 
wurden signifikant schlechtere Ergebnisse beim 5-Jahres DFS gemessen: 
Non-inferiority kann aber nicht ausgeschlossen werden, wenngleich inferio-
rity wahrscheinlicher ist. 
Bedenken zur Qualität der Evidenz und dem Verzerrungsrisiko bestehen 
wegen hoher Drop-Out Rate und open-label der Studie, der Indirektheit der 
Endpunkte (Surrogatendpunkte DMFS und DFS) und Impräzision (breite 
Konfidenzintervalle).  Zusätzlich fehlen Ergebnisse zur kurzfristigen wie 
langfristigen QoL (aufgrund von Toxizitäten) in beiden Gruppen, um Aussa-
gen zur Überlegenheit zu machen. 
 
Ergebnisse in der CL/GH Population (n=344 vs. 346): In dieser PatientIn-
nengruppe (ITT Analyse) ist adjuvante Chemotherapie – entsprechend der 
klinisch-pathologischen Risikoabschätzung (AO!)  –  nicht indiziert, wohl 
aber basierend auf MammaPrint®. Der Risikounterschied zwischen 
MammaPrint® vs. vs. AO! betrug  
b 0,8% bei 5-Jahres DMFS 95,8% (95% CI 92,9-97,6) mit Chemothera-
pie vs. 95,0% (95% CI 91,8-97,0) ohne Chemotherapie (HR 1,17; 95% 
CI 0,59-2,28; p=0.66; nicht statistisch signifikant) – zuungunsten von 
MammaPrint®,  
b 2% bei 5-Jahres DFS 92,1% (95% CI 88,3-94,6) mit Chemotherapie 
vs. 90,1% (95% CI 86,1-93,0) ohne Chemotherapie (HR 0,87; 95% CI 
0,53-1,45; p=0.60; nicht statistisch signifikant), 
b 0,7% bei 5-Jahres OS 97,1% (95% CI 94, 5-98,5) mit Chemotherapie 
vs. 97,8% (95% CI 95,5-99,0) ohne Chemotherapie (HR 1,28; 95% CI 
0,54-3,02; p=0.58; nicht statistisch signifikant) (nicht statistisch sig-
nifikant). 
Auch in dieser PatientInnengruppe konnte kein Zusatznutzen von 
MammaPrint®  nachgewiesen werden, wobei MINDACT aber nicht ausrei-
in CH/GL Population 
(n=542 vs. 503 Pts):  
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chend gepowered war, um statistisch signifikante Unterschiede zwischen 
den Gruppen zu zeigen. Demnach kann ein klinischer Nutzen als Entschei-
dungsinstrument auch nicht ausgeschlossen werden. 
 
Diskussion und Schlussfolgerung:  
Aus Perspektive von Kostenträgern ist ein valider Vergleich zwischen der 
etablierten Methode der Risikoabschätzung auf ein Rezidivrisiko nach pri-
märem Brustkrebs und einer neuen Methode zusätzlich zur herkömmlichen 
Methode für Refundierungsentscheidungen unabdingbar. In der MINDACT 
Studie wurden nur PatientInnen mit diskordanten Ergebnissen aus klinisch-
pathologischer und aus genomischer Risikoabschätzung miteinander vergli-
chen. Aus PatientInnen wie Kostenträger-Perspektive ist Frage nach einem 
möglichen Verzicht auf eine Chemotherapie hoch relevant. Bei Gleichwertig-
keit der Risikoabschätungen (unter Akzeptanz der 3% Schwelle) wäre eine 
nachgewiesene Überlegenheit bei Lebensqualität wünschenswert. Solche 
Daten liegen allerdings nicht vor. 
Die Ergebnisse zeigen, dass der Nutzen von MammaPrint®, gemessen an 
den Endpunkten Fernmetastasen-freies Überleben (DMFS), krankheitsfreies 
Überleben (DFS) und Gesamtüberleben (OS) nach fünf Jahren unsicher und 
der etablieren Risikoeinschätzung nicht überlegen ist und daher der Verzicht 
auf eine Chemotherapie insb. bei PatientInnen mit hohem Rezidivrisiko nicht 
zu rechtfertigen ist. In der MINDACT Studie wurden die patientenrelevanten 
Endpunkte 10-Jahres-Überlebensrate, Lebensqualität und Nebenwirkungen 
einer Chemotherapie nicht erhoben und es liegt daher dazu keine Evidenz 
vor. 
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1 SUMMARY OF CLINICAL UTILITY OF MAMMAPRINT® 
 
1.1 Scope  
 
The scope of the project can be found here.  
 
1.2 Introduction 
 
Health problem 
The target population in this assessment is patients with early breast cancer. Early breast 
cancer is defined as invasive cancer that is confined to the breast and/or has spread to a 
limited number of axillary lymph nodes but not metastasised to distant parts of the body 
(A0002). 
 
Overall, breast cancer has a relatively good prognosis: about 80% of patients with breast 
cancer are still alive ten years after diagnosis. In women diagnosed with stage I and II breast 
cancer, overall five-year survival is 87-98% and ten-year survival is 78%-94% (A0023). 
 
The mainstay of the management of early breast cancer is locoregional treatment with surgery 
alone or combined with radiotherapy. The aim of adjuvant systemic chemotherapy is to treat 
subclinical metastases already present at diagnosis in order to prevent the subsequent 
development of distant metastases. However, 60-70% of patients with early breast cancer 
appear to be free of subclinical metastases at diagnosis so do not develop distant metastases 
with locoregional management alone [1]. There is, therefore, considerable controversy with 
regard to the optimal definitions and assessment of risk of relapse in women with early-stage 
breast cancer. Improved prognostic tools are needed to prevent overtreatment with adjuvant 
chemotherapy, which carries a risk of late toxicity (especially cardiac toxicity and 
haematological malignancies) and consequent decreased quality of life (QoL) (A0007). 
Several gene expression signature (GES) tests have been developed to better select patients 
for adjuvant chemotherapy.  
 
This EUnetHTA assessment focuses on MammaPrint®, as it is currently the only GES test for 
which there is direct, peer-reviewed, published evidence of its clinical utility in the entire early 
breast cancer population.   
 
Description of technology 
MammaPrint® is a GES test that measures the expression of 70 genes related to metastatic 
cascade in breast cancer tissue acquired by biopsy or surgery. MammaPrint®  is marketed by 
Agendia (Amsterdam, The Netherlands; http://www.agendia.com). Using these 70 genetic 
markers, patients can be divided into low- and high-risk groups, which in turn supports clinical 
decision-making for adjuvant treatment. MammaPrint® has been prospectively validated for 
use in early-stage breast cancer patients with tumours <5 cm (T1, T2, or operable T3), and 0-
3 positive lymph nodes (N0-1) regardless of oestrogen receptor (ER) or human epidermal 
growth factor 2 (HER2) receptor status (B0001). 
 
The decision to administer adjuvant chemotherapy is usually based on clinicopathological risk 
assessment. A number of algorithms are currently used to predict survival and the utility of 
adjuvant therapy. For example, Adjuvant! Online (AO!) is a widely used web-based algorithm 
designed to provide estimates of the benefits of adjuvant endocrine therapy and 
chemotherapy. To provide estimates of risk reduction of breast cancer-related death or relapse 
at ten years, AO! uses information about the efficacy of different therapeutic regimens from 
the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis (B0001).  
 
Main research question of the EUnetHTA assessment  
In this EUnetHTA assessment the main research question is: does adding MammaPrint® to 
standard risk assessment with AO! in patients with a high clinical risk profile substantially and 
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positively affect the health and well-being of women with early breast cancer by limiting the 
number of patients receiving adjuvant chemotherapy and related adverse events, on the 
condition that survival is not negatively affected? From a reimbursement perspective, it is 
necessary that the new and standard approaches are compared.  
 
 
1.3 Assessment method for clinical utility 
 
The clinical utility was at first limited to randomised controlled trials (RCTs) because they 
provide the highest level of evidence for MammaPrint®’s clinical utility. Evidence on 
MammaPrint®’s clinical utility is available from one RCT, the Microarray In Node-negative and 1 
to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) study. Two 
prospective studies were also identified, but did not qualify as supportive evidence for clinical 
utility and were therefore excluded. From a reimbursement perspective, it is necessary that 
health-outcomes according to the new and standard approaches are compared. Part of the 
main research question of this EUnetHTA assessment is to prove that MammaPrint® does not 
negatively affect survival. This is a non-inferiority question, therefore a non-inferiority 
threshold must be specified. However, there is no international consensus on this non-
inferiority threshold, so a 3% difference in ten-year overall survival (OS) or a hazard ratio (HR) 
<0.8 in case of immature survival data was used based on the European Society for Medical 
Oncology criteria for the Magnitude of Clinical Benefit Scale (ESMO-MCBS) and a conventional 
trade-off between toxicity and efficacy [2,3]. Different scientific organisations and countries 
use different thresholds, so, during the reimbursement decision process, each country will 
need to decide individually which non-inferiority threshold to use. 
 
We used the Cochrane Risk of Bias Tool to assess internal validity. The quality of the evidence 
was assessed as part of examining the overall documentation for each outcome using Grading 
of Recommendations, Assessment, Development and Evaluation (GRADE) methodology.  
 
1.4 Results  
 
Characteristics of the available evidence 
One RCT (MINDACT) was identified [4]. MINDACT was an open-label, randomised controlled, 
phase 3 trial of women with early-stage breast cancer (n=6693, median follow-up five years). 
The investigators aimed to provide prospective evidence of the clinical utility of MammaPrint® 
added to standard clinicopathological risk assessment compared to standard clinicopathological 
risk assessment alone. MINDACT focused on discordant risk groups: a subgroup with a clinical 
high-risk profile discordant with a genomic low-risk profile (clinical high and genomic low; 
CH/GL) and a subgroup with a clinical low-risk profile discordant with a genomic high-risk 
profile (clinical low and genomic high; CL/GH). MINDACT’s primary objective was to assess 
whether chemotherapy could be safely withheld in the CH/GL subgroup without affecting 
distant metastasis-free survival (DMFS). The authors predefined the cut-off for non-inferiority 
as the lower boundary of the 95% confidence interval (CI) of the five-year rate of DMFS should 
be more than 92% in CH/GL patients who did not receive chemotherapy based on the 
MammaPrint® result. 
 
Results of the clinical high-risk and genomic low-risk population   
In case of the CH/GL population, the added value will not be in terms of survival, as 
MINDACT’s primary objective is not superiority but to safely spare chemotherapy in this group 
(non-inferiority in term of OS; PP analyse). The added value is that patients will potentially 
experience a better QoL (superiority in terms of QoL and toxicity; ITT analyse).  
 
Direct comparison of overall survival or surrogate outcomes (non-inferiority claim) 
Ten-year OS data is not yet available from the MINDACT study, so results of surrogate 
endpoints five-year DMFS, five-year disease-free survival (DFS) and five-year OS were 
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reported. In the PPS1 analysis, the risk differences in the CH/GL patients treated according to 
MammaPrint® compared to AO! were 2.5% for five-year DMFS (HR= 0.60; 95% CI 0.34-1.06; 
p=0.080), 4.5% for five-year DFS (HR=0.57;95% CI 0.37-0.87; p=0.009) and 1.8% for five-
year OS (HR of 0.54 (95% CI 0.23-1.26; p=0.154) all in advantage of AO! (Table 1.1). The 
differences in five-year DMFS and five-year OS were not significantly different. The 95% CIs of 
five-year DMFS and five-year OS crossed the non-inferiority threshold of HR 0.80, indicating 
non-inferiority of MammaPrint® is questionable. However, the point estimates were on the left 
side of the non-inferiority threshold. It is therefore reasonable to assume that using 
MammaPrint® may result in an increased risk of death due to distant metastasis, in comparison 
to AO! risk assignment. Although, the study was not adequately powered to assess statistical 
differences, MammaPrint® risk assignment led to a significantly worse five-year DFS. The 
upper 95% CI boundary of 0.87 is above the non-inferiority threshold of 0.80, which means 
that non-inferiority in terms of OS cannot be ruled out. However inferiority is more likely since 
the lower boundary of the 95% CI of 0.37 and the point estimate of 0.57 both crosses the 
ESMO-MCBS threshold of 0.65 (GRADE A)2, indicating DFS was significantly and clinically 
relevant worse in patients in whom treatment was based on MammaPrint®. For those HTA-
organisations that use risk differences in their assessment the same conclusion can be made. 
The risk differences are 2.5% for five-year DMFS and 4.5% for five-year DFS and 1.8% for 
five-year OS. The absolute risk difference of five-year DFS (4.5%) crosses the non-inferiority 
threshold of 3%. Those of DMFS and OS (2.5% and 1.8% respectively) do not cross the non-
inferiority threshold, but since in general the confidence intervals are large, it is reasonable to 
assume that also for five-year DMFS and five-year OS the required non-inferiority is not 
shown.   
 
The quality of the evidence for the critical ten-year OS endpoint was low (when five-year DMFS 
and DFS were used as surrogates) to very low (when direct measurements of OS but only five-
year data was used). Low quality was due to concerns about a risk of bias (considerable 
number of drop-outs and open-label study), indirectness (use of surrogate endpoints), and 
imprecision and very low (five-year OS) due to additional imprecision (crossing both 
thresholds). For these reasons, confidence in the OS effect estimate after ten years is at best 
limited, and the true effect may be substantially different. 
 
Direct comparison of outcomes on quality of life and toxicity (superiority claim) 
MINDACT did not evaluate long-term health-related quality of life (QoL). It may be argued that 
some aspects of QoL are reflected by other outcomes. It is obvious that the QoL of patients 
receiving adjuvant chemotherapy will be reduced due to chemotherapy side effects during and 
shortly after treatment compared to patients who do not receive chemotherapy. On the other 
hand, the MINDACT study shows that refraining from chemotherapy leads to a significant and 
clinically-relevant worse five-year DFS. Recurrences of all types are stressful to patients even 
in the case of a curable disease. This distress will have its repercussions on quality of life. 
Short- and long-term side effects of chemotherapy were measured, but these results have yet 
to be published. In the absence of data on QoL and toxicity the superiority in terms of QoL 
cannot be quantified.  
 
Results of the clinical low-risk and genomic high-risk population 
In addition to the main EUnetHTA research question, this assessment also examined the added 
value of MammaPrint® in the other discordant risk group (CL/GH). In this case, adjuvant 
chemotherapy is not indicated according to standard clinical risk assessment, but is indicated 
when based on the MammaPrint® result. Therefore, the added value is in terms of OS and 
hence the ITT population data is presented.  
                                               
1
 Due to the temporary change in risk as a result of assay problems, all risk groups as enrolled in that particular period are 
somewhat biased due to incorrect risk assessment. In addition to the prespecified PP analyses, also so-called PPS analysis is 
presented in the MINDACT publication, in which all patients enrolled during the period of change in risk were excluded. This PPS 
analysis represents the least biased and therefore most conservative PP analysis. 
2
 ESMO describes the highest level of clinical benefit (GRADE A) <0.65 and <0.80 as GRADE B. 
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CL/GH patients who after randomisation received chemotherapy on the basis of genomic risk 
had a five-year DMFS rate of 95.8% (95% CI 92.9-97.6), whereas those not receiving 
chemotherapy (randomly assigned based on clinical risk) had a 0.8% lower five-year DMFS 
rate of 95.0% (95% CI 91.8-97.0). However, this difference was not statistically significant 
(p=0.657). The five-year DFS surrogate endpoint was 92.1% (95% CI 88.3-94.6) for patients 
who received chemotherapy (on the basis of genomic risk) and 90.1% (95% CI 86.1-93.0) for 
patients who did not receive chemotherapy (based on clinical risk), 2.0% lower than the rate 
among those who received chemotherapy based on the MammaPrint® result (p=0.603). For 
five-year OS, 97.1% (95% CI 94.5-98.5) of patients who received chemotherapy (based on 
genomic risk) and 97.8% (95% CI 95.5-99.0) of patients who did not receive chemotherapy 
(based on clinical risk) were still alive, 0.7% lower in those who received chemotherapy based 
on the MammaPrint® result (p=0.578) (Table 1.1). None of the surrogate endpoint differences 
were significant, and added value of MammaPrint® has not been demonstrated at this time. 
However, the study was not powered to assess significant differences in this discordant group, 
so a clinical benefit for MammaPrint®-based treatment decision-making cannot be ruled out.  
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Table 1.1 Summary table of relative effectiveness of the MammaPrint® assay 
Early breast cancer 
 Health benefit   Harm 
 DMFS 5y 
HR (95% CI) 
p-value 
DFS 5y 
 HR (95% CI) 
OS 5y 
 HR (95% CI) 
QoL 
  
Short-term side 
effect of 
chemotherapy 
Long-term side 
effect of 
chemotherapy 
Clinical high/Genomic 
low (PPS) 
      
MammaPrint® + AO! 
(n=542) 
 
 
 
 
                          AO! 
                         (n=503) 
0.60 (0.34-1.06) 
p=0.08 
 
Using clinical risk 
96.5 (94.1-97.9) 
Using genomic 
risk 
94.0 (91.4-95.8) 
0.57 (0.37-0.87) 
p=0.01 
 
Using clinical risk 
93.3 (90.3-95.4) 
Using genomic 
risk 
88.8 (85.7-91.3) 
0.54 (0.23-1.26) 
p=0.15 
 
Using clinical risk 
98.8 (97.1-99.5) 
Using genomic risk 
97.0 (94.9-98.2) 
Not 
measured# 
Not reported Not reported 
Quality of body of 
evidence+  
⨁⨁◯◯ 
 Low (1) 
⨁⨁◯◯ 
 Low (1) 
⨁◯◯◯ 
Very low (2) 
   
Clinical low/ 
Genomic high (ITT) 
      
MammaPrint® + AO! 
(n=344) 
 
 
                              AO! 
                          (n=346) 
1.17* (0.59-2.28) 
p=0.66 
 
Using clinical risk 
95.0 (91.8-97.0) 
Using genomic 
risk 
95.8 (92.9-97.6) 
0.87*(0.53-1.45) 
p=0.60 
 
Using clinical risk 
90.1 (86.1-93.0) 
Using genomic 
risk 
92.1 (88.3-94.6) 
1.28* (0.54-3.02) 
p=0.58 
 
Using clinical risk 
97.8 (95.5-99.0) 
Using genomic risk 
97.1 (94.5-98.5) 
Not 
measured# 
Not reported Not reported 
Quality of body of 
evidence+ 
⨁◯◯◯ 
Very low (3) 
⨁◯◯◯ 
Very low (3) 
⨁◯◯◯ 
Very low (3) 
   
Abbreviations: DMFS: distant metastasis-free survival; DFS: disease-free survival; OS: overall survival; QoL: quality of life; PPS: per protocol sensitivity population, ITT: 
intention to treat population 
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+ Quality of the body of evidence was rated using GRADE. The interpretation is: high, confident that the true effect lies close to that of the estimated effect; moderate, 
moderately confident in the effect estimate, the true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different; low, limited 
confidence in the effect estimate, the true effect may be substantially different from the estimated effect; very low, very little confidence in the estimated effect, the true effect 
is likely to be substantially different from the estimated effect.  
(1) Downgraded twice due to concerns about risk of bias (open-label study and amount of drop-outs), indirectness (surrogate endpoints), and imprecision; 
(2) Downgraded three times due to concerns about risk of bias, indirectness and imprecision; 
(3) Downgraded three times due to concerns about indirectness (once) and imprecision (twice). 
* The HRs are not concordant with the DFS and OS rates after a median follow-up of five years of the MINDACT.  
#QoL was measured in 347(566 enrolled) patients but only six-eight weeks after surgery and not during/directly after chemotherapy and not in the long term. Therefore this 
study could not be used to determine a difference in QoL in the long term between the patients that received treatment based on the MammaPrint® result and patients that 
received treatment based on the AO!.   
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1.5 Discussion 
 
From a reimbursement perspective, a comparison must be made between the new and the 
standard approach because added value needs to be proven if a test or intervention is added 
to standard care. MINDACT does not have a formal non-inferiority design, because such a trial 
would either need to be extremely large or of long duration. In MINDACT’s first secondary 
analysis, outcomes were compared for patients in discordant risk groups according to whether 
risk assessment based on MammaPrint® (as an add-on) or AO! was used to assign patients to 
the chemotherapy or non-chemotherapy group. This comparison is of primary importance for 
reimbursement decisions for MammaPrint®.  
 
Based on the MINDACT it cannot be concluded that it is safe to omit chemotherapy, because 
the 95% CI’s of all surrogate outcomes for ten-year OS (five-year DMFS, five-year DFS and 
five-year OS) are crossing the non-inferiority threshold (HR 0.80 and 3% risk difference). Even 
the results of five-year DFS indicate that MammaPrint® is possibly clinically relevant inferior in 
comparison with treatment based on AO!. 
 
In addition, there are three main observations that underline the uncertainty with respect to 
the safety of omitting chemotherapy based on MammaPrint®: 
 
First, the surrogate five-year DFS endpoint showed a statistically and clinically relevant worse 
outcome (p=0.009) for MammaPrint® patients. It is plausible that the investigated group was 
large enough to reveal an effect on DFS even without the power being calculated for this 
secondary analysis. Since all outcome measures point in the same direction, it is less likely 
that this effect is merely due to chance when no true difference between the groups existed.  
 
Second, the study was not powered to assess statistically significant differences, so the 
absence of a significant DMFS and OS difference should not be interpreted as evidence of 
absence of an effect.  
 
Third, and related to the second observation, all surrogate outcomes had wide confidence 
intervals. Expressed as absolute numbers, introducing MammaPrint® can lead to 100 (of 1000) 
more patients not free of distant metastases after five years compared to AO!-based treatment 
decisions. Considering the 955 CI of five-year DMFS, it could also lead to six per 1000 less or 
at worst 287 per 1000 more patients not free of distant metastases after five years. This CI 
highlights the degree of uncertainty, and there remains a possibility that many patients could 
be harmed.  
 
1.6 Conclusion on clinical utility 
 
Each HTA-organisation will need to decide individually which non-inferiority threshold and 
clinical relevant thresholds are considered most appropriate for their assessment considering 
the local context. Based on the chosen thresholds in this EUnetHTA assessment report, 
conclusions are as follows: 
 
Taking everything into consideration, it has not yet been demonstrated that patient outcomes 
(ten-year OS and QoL) are improved by withholding adjuvant chemotherapy based on 
MammaPrint® testing in the CH/GL risk group. In other words, the clinical utility of the 
MammaPrint® is not proven. This conclusion is based on the absence of evidence on added 
value in terms QoL and on the fact that non-inferiority in terms of OS (surrogates five-year 
DMFS, five-year DFS and five-year OS) is not shown. In addition, there are concerns about the 
certainty of DMFS because of the imprecision (very wide 95% CI’s). Therefore the results do 
not rule out the possibility of a clinically-relevant increase in distant metastasis and hence risk 
of death. Also, the significant and clinically-relevant difference in DFS is of importance as QoL 
data is not available. The quality of the evidence for the critical ten-year OS endpoint was 
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rated as low to very low. Therefore, the confidence in the OS effect estimate after ten years is 
limited at best. 
 
Furthermore, a clinical benefit of receiving chemotherapy in the CL/GH risk group according to 
genomic risk assignment has not been demonstrated. The quality of the evidence for the 
critical ten-year OS endpoint was rated very low. Therefore, there is very little confidence in 
the effect estimate, and the true effect is likely to be substantially different from the effect 
estimate.  
 
Ten years of follow-up will be needed to conclude if an add-on risk assessment approach (AO! 
combined with MammaPrint®) has superior clinical utility compared with treatment decisions 
based on AO! alone. At that time, the level of evidence of the data and therefore confidence in 
the data will be higher, because the use of surrogate endpoints will no longer be necessary. If 
a revision of AO! becomes available, as it is expected, this could have an impact on the 
baseline risks of recurrence and hence may potentially limit the clinical applicability of the 
MINDACT results. 
 
Ultimately, the decision to receive or forgo chemotherapy (or any other treatment) lies with 
each patient who is properly informed about the potential side effects and the potential 
benefits of such treatment. For the same risk–benefit scenario, different patients may make 
different decisions. However, well-informed decision making is only possible if both parameters 
(OS and QoL) has been quantified.  
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2 SCOPE  
 
2.1 Background 
 
Gene expression signature tests (GES tests) such as the MammaPrint® 70-gene signature have 
the potential to provide prognostic information to distinguish early-stage breast cancer 
patients who are likely to remain free of distant metastases from patients who are likely to 
develop distant metastasis. These GES tests aim to improve the information on a patient’s risk 
of (distant) recurrence in guiding therapy to patients who will benefit most from adjuvant 
chemotherapy from those who will have limited benefit.   
 
The scope of this EUnetHTA assessment focuses on the direct evidence of clinical utility of GES 
tests in treatment decision-making on adjuvant chemotherapy. A scoping search was 
undertaken to define the scope. First, the background of the current assessment is presented 
through a short narrative of the scoping search results. 
 
Reviews covering the literature from 1990 to 2014 concluded that, of the evaluated tests, 
Oncotype DX® and MammaPrint® were the furthest along their validation pathways (Table A1, 
Appendix 1). The majority of the literature provide evidence on test performances, such as 
the analytic validity (test performances on repeatability and reproducibility) and the clinical 
validity (prognostic ability in the case of GES, calibration, discrimination, re-/classification) [5-
8]. Given that these GES tests were developed as prognostic tests more than as predictive 
tests and that clinical implementation was already underway, subsequent reviews focused on 
the clinical utility of Oncotype DX® and MammaPrint® [9,10]. Clinical utility refers to the test’s 
ability to predict or identify the patients who will have more or less benefit of a therapeutic 
intervention. From 2014 onwards the available evidence of clinical utility evaluated indirect 
outcomes of clinical utility, such as the impact of GES on reclassification of risk in clinical 
practice, or evaluating the correlations between test score and score on existing measures 
based on decision-making tools such as the Nottingham Prognostic Index (NPI) and AO!. In 
contrast to indirect evidence of clinical utility, direct evidence evaluates the overall 
improvement in patient-relevant treatment outcomes by directly comparing treatment 
outcomes using the GES test to guide treatment decisions, with treatment outcomes using 
commonly established risk criteria not incorporating findings from the GES test. Although the 
scoping search was limited to the English and Dutch languages, one English executive 
summary was identified which outlined the main conclusions of a systematic review originally 
written in German by the Institute for Quality and Efficiency in Health Care (IQWiG). This 
review included one study that may provide direct evidence of clinical utility: a randomised 
study evaluating MammaPrint® (MINDACT) [11]. The other included studies in this review 
evaluated indirect evidence of other GES tests. In summary, with the latter review included, it 
was concluded that there is no proven benefit from using a GES test. As the vast majority of 
the currently available evidence is indirect, direct evidence of the clinical utility of GES tests is 
still needed.  
  
Randomised studies provide level 1 evidence on patient benefit, potentially endorsing 
widespread clinical use. The scoping search identified three ongoing randomised studies: 
MINDACT (MammaPrint®), TAILORx (Oncotype DX®), and RxPONDER (Oncotype DX®). These 
studies will provide direct evidence of clinical utility using a randomised controlled study design 
that follows patients from initial diagnosis through to final health outcomes. The current 
EUnetHTA assessment focuses on MammaPrint®, as it is currently the only GES test for which 
results with regard to direct evidence of clinical utility on the entire early-stage breast cancer 
population have been published in a peer-reviewed journal. In assessing clinical utility, we 
consider it as important that the GES test should be performed on the entire early-stage breast 
cancer population in order to identify all patients who would have been treated differently by 
using the GES test. This will allow the direct comparison of the treatment outcomes using the 
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GES test and the treatment outcomes using commonly established risk criteria. The TAILORx 
study and the RxPONDER study were ongoing at the time of the current EUnetHTA 
assessment. The results of the TAILORx study are due to be published in December 2017, and 
the results of RxPONDER are due within the next few years.   
 
2.2 Main research question of this EUnetHTA assessment 
 
In this EUnetHTA assessment the main research question is: does adding MammaPrint® to 
standard risk assessment with Adjuvant! Online in patients with a high clinical risk profile 
substantially and positively affect the health and well-being of women with early breast cancer 
by limiting the number of patients receiving adjuvant chemotherapy and related adverse 
events, on the condition that survival is not negatively affected? 
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2.3 Scope 
 
Description Project scope 
Population  
 
Early-stage breast cancer patients (pT1-2, operable T3, N0-1,cM0) 
ICD-10: C50 
MeSH: Breast neoplasms 
Intervention  
 
MammaPrint®  
 
MammaPrint® is a gene expression signature test used to decide on 
whether to administer adjuvant chemotherapy. MammaPrint® will be 
assessed as an add-on to standard clinicopathological criteria using the 
Modified Adjuvant! Online (and as a replacement). 
 
Technology: MammaPrint® is a prognostic genomic test that aims to 
provide a risk assessment of mamma carcinomas by providing a risk 
profile (i.e., low or high) of the chance of developing distant metastases.  
MammaPrint® is a gene expression signature test that measures the 
expression of 70 genes in cancerous breast tissue. 
 
MeSH: Gene expression profiling 
Comparison 
 
Modified Adjuvant! Online is an online decision tool used to decide on 
whether to administer adjuvant chemotherapy. 
 
Modified Adjuvant! Online was chosen as the comparator.  
 
Treatment decision-making on adjuvant chemotherapy is based on 
clinicopathological risk criteria (modified Adjuvant! Online): a high clinical 
risk means that adjuvant chemotherapy is indicated, and a low clinical 
risk means that no adjuvant chemotherapy is indicated.  
 
Outcomes 
 
Critical endpoints for relative effectiveness/safety 
• Ten-year overall survival (OS)  
• Health-related quality of life (QoL) 
• Short- and long-term side effects from chemotherapy such as 
cardiovascular and haemato-oncologic toxicity such as (sub-)clinical 
cardiac failure or secondary leukaemia, respectively 
 
If necessary, surrogate endpoints will be included. The relation between 
the surrogate endpoint and critical endpoint will be described.   
Study design 
 
Effectiveness/safety 
• Randomised controlled trial (RCT) 
• If evidence from RCTs is limited, prospective observational studies will 
be considered for inclusion to provide more stable estimates of clinical 
utility. 
Follow-up 
time 
Follow-up time should be at least ten years and, if unavailable, shorter 
follow-up times where acceptable surrogate endpoints are available will 
be considered.  
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3 METHODS AND EVIDENCE INCLUDED  
 
3.1 Assessment team 
 
The tasks were assigned to the agencies as follows:  
As Author, ZIN:  
• Played a leading role in both scoping and production of the clinical utility assessment; 
• Was responsible for the management of the completed scientific work; 
• Had ultimate responsibility for quality assurance; 
• Answered comments. 
 
For collaborative assessments, the following mode of assessment was pursued: 
The 1st authors (AL and YK) were responsible for the production of all domains, including data 
extraction from clinical trials, finding answers to the questions listed in the Project Plan, and 
writing the assessment. A third ZIN reviewer (HS) followed and verified every step taken by 
the 1st authors during the production of the assessment including data extraction, verification 
of references, risk of bias tables, and adherence to methods.  
 
As Co-author of the clinical utility assessment, KCE: 
• Was responsible for supporting the author in all project phases; 
• Was responsible for reviewing all domains including the clinical utility domain. 
 
As Dedicated Reviewers, LBI-HTA and HAS:  
• Guaranteed quality assurance by thoroughly reviewing the project plan and the assessment 
drafts; 
• Reviewed methods, results, and conclusions based on the original studies included;  
• Provided constructive comments in all project phases. 
 
3.2 Scoping meeting/patient involvement 
 
A scoping meeting was organised at the start of the assessment where representatives of 
Dutch patients, clinicians, hospitals, and healthcare insurers were present (09.03.2017 at 
Zorginstituut Nederland at Diemen). During this meeting, the Population, Intervention, 
Comparator, and patient-related Outcomes (PICO) were discussed. All relevant parties agreed 
with the PICO as described in this assessment. The experts were asked what threshold for 
clinical relevance is being used by their scientific societies. During the phase of written 
consultation of the assessment patient representatives and external experts (clinicians) were 
consulted. KCE also organised a scoping meeting at the start of the assessment regarding the 
cost-effectiveness of the MammaPrint® where clinicians and scientist/data-analysts were 
present. This group of experts could also find themselves in the PICO as described.   
 
3.3 Source of assessment elements  
 
The assessment element selection was based on the HTA Core Model® Application for Rapid 
REA Assessments. The selected issues (generic questions) were translated into actual research 
questions (answerable questions). 
 
3.4 Search  
 
Current use of technology (CUR) domain 
This domain was developed starting with the information provided by the manufacturer within 
the Manufacturer’s Submission File. A face-to-face meeting with Agendia was organised on 
20.12.2016. In addition to the information provided in the Submission File, information was 
integrated with selected scoping searches, ad hoc PubMed and internet searches of the grey 
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literature using the Google search engine, review of the reference lists and bibliographies of 
the studies identified through the basic selective search, manufacturers’ websites, brochures, 
and information for use. 
 
 
Technical characteristics of the technology (TEC) domain 
This domain was developed starting with the information provided by the manufacturer within 
the Manufacturer’s Submission File. In addition to the information provided in the Submission 
File, information was integrated with ad hoc PubMed and internet searches of the grey 
literature using the Google search engine, review of the reference lists and bibliographies of 
studies identified through the basic selective search, manufacturers’ websites, brochures, 
information for use, and regulatory bodies’ databases. 
 
Clinical effectiveness (EFF) and safety (SAF) domains 
These domains were developed using a systematic structured literature search. The following 
databases were searched: 
• MEDLINE; 
• Embase;  
• Cochrane Library.  
 
Search strategy 
For the clinical utility outcome, direct evidence from a RCT was necessary. The evidence base 
covering literature from 1990–2014 established that MammaPrint® (next to Oncotype DX®) 
was the furthest along the pathway of analytic and clinical validation. Given that these GES 
tests were developed as prognostic tests and not as predictive tests, and that clinical 
implementation was already underway, subsequent reviews highlighted the need for direct 
evidence of the clinical utility of Oncotype DX® and MammaPrint®. Therefore, the current 
search strategy on the clinical utility of MammaPrint® included all relevant available literature 
on MammaPrint® from June 2014 (KCE search date). In addition, information provided in the 
Manufacturer’s Submission File and recent literature updates provided by the manufacturer 
during the assessment period were integrated in the search. 
 
MeSH terms (see Appendix 1, Section 9.2) were combined with the following terms to 
perform the searches: “MammaPrint®” (non-MeSH) or “70-gene” or “70 gene” or “MINDACT”. 
As we anticipated that few RCTs had been conducted, we did not include the MeSH term 
“Randomised Controlled Trial” to identify potential supporting evidence from studies with a 
lower level of evidence. Therefore, no limits relating to study design were applied. 
 
All searches were limited to English and Dutch language sources published between June 2014 
(date of KCE literature search [5] and the time of searches (April 11th 2017). 
In addition, the following clinical trials databases were searched to identify on-going trials or 
studies: 
• ClincalTrials.gov;  
• Cochrane Register of Controlled Trials; 
• https://www.clinicaltrialsregister.eu/. 
 
If possible and of added value, results for the following subgroups (or combinations) were 
presented: 
• Low clinical risk population; 
• High clinical risk population; 
• ER status; 
• HER2 status; 
• Lymph node status. 
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Inclusion and exclusion criteria 
Publications on studies with a RCT design were included for the assessment of clinical utility. 
As described above, to capture all the available literature on direct evidence of clinical utility 
we did not include limits relating to study design for supportive evidence. However, supportive 
evidence from studies of a lower level of evidence were only included when prospectively 
obtained data with sufficient follow up were available of patients with discordant test results to 
allow for the direct comparison of the treatment outcomes using the MammaPrint® test and 
the treatment outcomes using commonly established risk criteria. 
 
The following publication types were excluded: retrospective studies, technical and/or clinical 
validation studies; non-early breast cancer patients; studies on neoadjuvant chemotherapy; 
animal models, preclinical and biological studies; editorials, reviews, guideline publications, 
expert opinions; histologic types other than ductal carcinoma; abstracts, posters; and non-
peer-reviewed publications.  
 
3.5 Data extraction strategy and flow chart of study selection  
 
Two authors screened the records by title and abstract. Disagreements were solved by 
discussion. The full text of potentially relevant studies were retrieved and reconsidered for 
actual inclusion in the current evidence review. The two researchers performed data extraction 
independently. The retrieved data were cross-checked against the submission file received 
from the manufacturer for completeness. If necessary, additional data was extracted from 
original papers. Subsequently, a third reviewer verified the references and the information 
retrieved from the extracted publications. See Figure 3.1. 
 
Description of excluded records 
Based on title and abstract, records were excluded for the following reasons: guideline 
publications (n=3); comments, letters and reviews (n=16); miscellaneous reasons (n=26 for 
reasons of neo-adjuvant setting, other histologic type (not ductal carcinoma), pre-clinical 
setting, concordance studies, cost-effectiveness studies, other language and not related to 
GES). Studies on technical and clinical validation were excluded (n=12), including studies with 
a retrospective-prospective design. These studies retrospectively analyse archived tumour 
samples derived from prospectively selected cohort(s) of patients with documented information 
on baseline recurrence risks based on standard clinicopathological criteria and treatment 
outcomes after re-classification based on MammaPrint®. This design is associated with 
increased bias compared to prospectively planned studies. These studies were considered as 
prognostic validation or hypothesis generating studies and therefore cannot be considered as 
supportive evidence on the clinical utility of the MammaPrint®. In addition, decision impact 
studies (n=5) were excluded when no data was provided in which health related treatment 
outcomes, such as OS (or surrogates) or QoL, according to MammaPrint® risk assessment 
were directly compared with health related treatment outcomes according to standard risk 
assessment in the patients with discordant test results. These studies were not considered as 
direct evidence on clinical utility of the MammaPrint® and for this reason excluded as 
supportive evidence. 
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Figure 3.1 Flow chart of study selection 
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3.6 Description of the evidence used 
 
Three potentially relevant studies were retrieved for full text reconsideration of direct evidence 
of clinical utility. Evidence on the clinical utility of the 70-gene profile (MammaPrint®) was 
available from one RCT (MINDACT) only. One prospective observational study evaluating 
clinical utility was also identified (The microarRAy-prognoSTics-in-breast-cancER (RASTER) 
study), in which survival data (OS or a surrogate) was reported [12]. However, the OS (or 
surrogate) for the discordant risk groups was not reported separately for those who did and 
did not receive chemotherapy following either standard risk assessment or the MammaPrint® 
respectively. In contrast, only the results of the discordant group (CH/GL) as a whole were 
published in which 44% of the patients received chemotherapy and 56% did not, and not the 
treatments outcomes of the CH/GL patients that received chemotherapy separately from those 
who did not receive chemotherapy. For this reason, this prospective study did not qualify as 
supportive for direct evidence of clinical utility and was therefore excluded. QoL was measured 
by Retel et al [13] in 347 (566 enrolled) patients of the MINDACT. The primary aims of the 
study were to evaluate the association between breast cancer patients’ well-being and the 
results of a gene expression profile on to compare different recurrence risk groups, according 
to their genomic and standard clinical risk assessment. Different questionnaires were taken to 
assess the QoL. The QoL was assessed 6-8 weeks after surgery. This study does not compare 
QoL in the long term between CH/GL patients receiving treatment based on the MammaPrint® 
result and receiving treatment based on the AO!. Therefore, this study was not qualified as 
supportive evidence on clinical utility.    
All relevant information about the included study is described in Table A5 of Appendix 1.In 
Table A6 of Appendix 1 the excluded studies and reasons for exclusion are presented.  
 
MINDACT 
MINDACT is an international, open-label, randomised, controlled, phase 3 trial in women with 
early-stage breast cancer (n=6693, five-year median follow-up period) comparing standard 
clinicopathological risk profiling with MammaPrint® 70-gene risk profiling added to standard 
clinicopathological criteria based on a modified version of AO! for selecting patients for 
adjuvant chemotherapy. In MINDACT, 6693 patients were enrolled in 112 institutions in nine 
European countries between 2007 and 2011. Eligible patients were women between aged 
between 18 and 70 years with histologically confirmed primary invasive breast cancer (stage 
T1, T2, or operable T3). The primary objective of MINDACT was to assess whether, in patients 
with high clinical risk and low genomic risk (CH/GL) in whom chemotherapy was withheld, the 
lower boundary of the 95% CI for the five-year distant metastasis-free survival (DMFS) rate 
would be 92% (i.e., the non-inferiority boundary) or higher at a one-sided significance of 
0.025. 
 
The study consisted of three consecutive randomisations. In the treatment randomisation (R-T 
randomisation), patients with discordant risk scores were randomly assigned to the 
chemotherapy group or the no-chemotherapy group on the basis of either the clinical or the 
genomic result.  
The treatment randomisation (R-T randomisation) used a minimisation technique that was 
stratified according to institution, risk group, HR status, nodal involvement, age (<50 years vs. 
≥50 years), HER2 status, axillary treatment (sentinel node only vs. dissection), and type of 
surgery (mastectomy vs. breast conservation). Two additional (optional) randomisations were 
conducted, in which patients who were assigned to receive adjuvant chemotherapy (R-C 
randomisation; either randomly because of discordant results or due to high-risk concordance 
in both tests) could be randomly assigned to receive an anthracycline-containing regimen or a 
docetaxel-plus-capecitabine regimen. Similarly, patients with hormone receptor-positive breast 
cancer could undergo further randomisation to a tamoxifen-letrozole regimen or a letrozole-
only regimen (R-E randomisation). The current publication of Cardoso et al. [4] focuses on the 
results of the R-T randomisation only.  
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In the RT-randomization, three pre-specified secondary analyses were conducted. The first 
pre-specified secondary analysis evaluated patient outcomes in the discordant risk groups 
according to whether the patients were assigned to the chemotherapy group or the no-
chemotherapy group. In the second pre-specified secondary analysis, the outcomes of all 
patients according to whether chemotherapy had been recommended by either clinical or 
genomic risk alone were evaluated. In the third pre-specified secondary analysis, the 
percentage of all enrolled patients who would be assigned to chemotherapy on the basis of 
either clinical risk or genomic risk was evaluated. The main characteristics of MINDACT are 
described in Table 3.1 and Table A5 in Appendix 1. 
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Table 3.1 Main characteristics of studies included  
Author and 
year or 
study 
name 
Study 
type 
Number of 
patients 
Intervention(s) Main endpoints Sponsoring 
Cardoso et 
al. 2016 
MINDACT 
[4] 
RCT 6693 Experimental: 
MammaPrint® added to Adjuvant! 
Online to make “yes-no” decision 
on adjuvant chemotherapy.  
Comparator: 
Treatment decision based on 
Adjuvant! Online alone. 
 
Additional (optional) 
randomisations: 
• Chemotherapy randomisation: 
anthracycline or docetaxel-
plus-capecitabine regimen.  
• Hormone randomisation: 
tamoxifen-letrozole or 
letrozole-only regimen. 
Primary: five-year DMFS$ 
Secondary: Proportion of 
patients that received 
chemotherapy according to 
the clinical risk compared 
with the genomic risk. 
Five-year OS* 
Five-year DFS# 
 
 
The MINDACT trial was supported by grants 
from the European Commission Sixth Framework 
Program, the Breast Cancer Research 
Foundation, Novartis, F. Hoffmann-La Roche, 
Sanofi-Aventis, Eli Lilly, Veridex, the U.S. 
National Cancer Institute, the European Breast 
Cancer Council-Breast Cancer Working Group, 
Jacqueline Seroussi Memorial Foundation for 
Cancer Research, Prix Mois du Cancer du Sein, 
Susan G. Komen for the Cure, Fondation Belge 
contre le Cancer, Dutch Cancer Society, 
Genomics Initiative-Cancer Genomics Centre, 
Association le Cancer du Sein, Parlons-en!, the 
Brussels Breast Cancer Walk-Run and the 
American Women’s Club of Brussels, NIF trust, 
German Cancer Aid, the Grant Simpson Trust 
and Cancer Research UK, Ligue Nationale contre 
le Cancer, and the EORTC Cancer Research 
Fund.  
 
Whole-genome analysis was provided by 
Agendia without cost. 
Abbreviations: DFS: disease-free survival; DMFS: distant metastasis-free survival; OS: overall survival.         
Source: MINDACT 
$ Distant metastasis-free survival: survival without distant metastasis was defined as the time until the first distant metastatic recurrence or death from any cause. 
# Disease-free survival was defined as the time until first disease progression (loco-regional, distant relapse, ipsilateral or contralateral invasive breast cancer, ductal carcinoma 
in situ or an invasive second primary cancer, or death from any cause.  
* Overall survival was defined as the time until death from any cause. 
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3.7 Assessment method for clinical utility  
 
From a reimbursement perspective, the added value of a new intervention or diagnostic test 
must be proven compared to standard care. In this EUnetHTA assessment, the main research 
question was to assess whether MammaPrint®, when added to standard risk assessment, leads 
to a substantial positive effect on the health and well-being of women by limiting the number 
of patients receiving adjuvant chemotherapy and related adverse events, on the condition that 
survival is not negatively affected. The first randomisation in which the treatment decision is 
randomised, that is the R-T randomisation, was the analysis of interest for the assessment of 
clinical utility. In fact, MINDACT’s first pre-specified secondary analysis addressed the main 
EUnetHTA research question: to answer the question of whether it is safe to withhold 
chemotherapy based on genomic risk assignment, a direct comparison is required between 
patients in whom chemotherapy was withheld following genomic risk assignment vs. patients 
who received chemotherapy following standard risk assignment. By contrast, MINDACT’s 
primary analysis did not compare the two arms, instead focusing only on one arm. Hence, the 
primary analysis of the study did not address the current research question.  
 
3.7.1 When is clinical utility proven in the CH/GL risk group? 
If MammaPrint® is added to standard clinical risk assessment, MammaPrint® must add value in 
terms of health-related outcomes. In the case of the population with high clinical risk and low 
genomic risk (CH/GL), the added value will not be in terms of survival, as MINDACT’s primary 
objective is not superiority but to safely spare chemotherapy in this group (non-inferiority 
assessment). The added value (superiority assessment) is that patients will potentially 
experience a better QoL and fewer side effects from chemotherapy like cardiovascular toxicity 
and secondary haematological cancers. To determine clinical utility of MammaPrint® the 
weighing of positive and negative effects must lead to a benefit in terms of patient health 
related outcomes.  
 
The claimed benefit of the MammaPrint® is that treatment decision based on MammaPrint® 
does not lead to worse survival in comparison with AO!. This is a non-inferiority claim. In case 
of non-inferiority significant differences are irrelevant. Non-inferiority is shown when the 95% 
CI is entirely above the non-inferiority threshold. Figure 3.2 shows when non-inferiority is 
shown (orange and green line), questionable (blue line) and when there is (possible) inferiority 
(red and yellow line). The per protocol (PP) analysis of the OS data is reported. The PP analysis 
represents a conservative estimate of the possible harm of MammaPrint® as opposed to the 
ITT analysis, which tends to find no effect. In this case, one wants to be certain that a 
treatment decision to forgo adjuvant chemotherapy based on MammaPrint® does no harm in 
terms of OS. For this reason it was decided that the PP analysis should be used as by 
convention [14]. For the sake of completeness the ITT analyses are reported in full in Table 
6.1 and Table A14. 
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Figure 3.2 Concept of non-inferiority of OS in the CH/GL group 
 
 
X = the non-inferiority threshold  
 
In theory, this means that when non-inferiority of OS is shown (see orange1 and green line2 in 
Figure 3.2) and there is evidence of reduced toxicity and improved QoL, MammaPrint®’s 
clinical utility would be proven. When non-inferiority of OS is questionable (see the blue line3 in 
Figure 3.2), it cannot be ruled out that MammaPrint® use results in a clinically-relevant 
deterioration. In this case, positive effects on toxicity and QoL must outweigh a possible 
inferior effect on OS. When there is a statistically significant difference (red4 and yellow line5 in 
Figure 3.2), inferiority is likely but non-inferiority cannot be ruled out either (red line4) or 
inferiority is shown (yellow line5). HTA-organisations or countries possible will have different 
opinions if (possible) loss in OS can be outweighed by benefits in QoL and toxicity or not.   
 
3.7.2 When is clinical utility proven in the CL/GH risk group? 
In the case of adding MammaPrint® to the low clinical risk and a high genomic risk population 
(CL/GH), superiority in OS must be demonstrated, because chemotherapy is being given to a 
population that will not normally receive chemotherapy according to standard 
clinicopathological criteria.  
  
3.8 Method of quality rating the studies 
 
One RCT (MINDACT) was included in the assessment of clinical utility of MammaPrint®. The 
quality of this study was analysed using the Cochrane risk of bias checklist and GRADE. GRADE 
is used to qualitatively summarise results from the relative effectiveness and safety domains. 
No quality assessment tool was used for the TEC and CUR domains. Multiple sources were used 
to validate individual, potentially biased, sources. Descriptive analysis and synthesis were 
performed using different information sources. 
 
GRADE quality ratings reflect the certainty of evidence. It is therefore desirable to pre-specify 
the thresholds or ranges used to rate the certainty of evidence for individual outcomes. The 
available clinical thresholds are described below in Section 3.8.1. 
 
3.8.1  Clinical relevance thresholds 
To identify widely accepted clinical relevance thresholds, the literature was searched and 
experts were asked for clinically relevant differences in OS (or surrogates) for oncological 
interventions.  
 
Different scientific organizations and countries use different thresholds (see Table 3.2). From 
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a reimbursement perspective, the added value of a new intervention or diagnostic test must be 
proven compared to standard care. In this EUnetHTA assessment, the main research question 
was to assess whether MammaPrint®, when added to standard risk assessment, leads to a 
substantial positive effect on the health and well-being of women by limiting the number of 
patients receiving adjuvant chemotherapy and related adverse events, on the condition that 
survival is not negatively affected. To answer this question, a direct comparison between the 
two arms is required. By contrast, MINDACT’s primary analysis did not compare the two arms, 
instead focusing only on one arm. 92% was used as non-inferiority threshold in the MINDACT 
in case of a one-arm analysis, but cannot be used as a non-inferiority threshold in case of a 
risk difference between two arms. Therefore this MINDACT threshold of 92% cannot be used in 
this EUnetHTA assessment. Consequently, other literature on clinical relevance and non-
inferiority thresholds were searched (see Table 3.2). This list is not an exhaustive overview of 
thresholds used. Each country will need to decide individually which threshold to use. Even 
though MammaPrint® is a diagnostic test, and thresholds for clinical relevance are primarily 
developed to assess the efficacy of anticancer therapies, the thresholds can reasonably be 
used to determine the clinical utility of a diagnostic test because in case of clinical utility the 
added value of the ‘test plus treatment’ on health related outcomes needs to be proven. In the 
case of a diagnostic test which enables reclassification of prognostic risk, such as 
MammaPrint®, these thresholds can be applied to determine whether a difference in OS (or 
surrogate outcomes) is clinically relevant. Since the current case is to assess whether a risk-
difference in OS is clinically relevant to prove that MammaPrint®, is non-inferior, a threshold 
for non-inferiority is needed. However, there is no international consensus on non-inferiority 
thresholds (both in case of efficacy and in case of diagnostic tests). Tanaka et al. [14] 
concluded in a systematic review on cancer studies evaluating non-inferiority that selection of 
non-inferiority margins in early breast cancer studies is frequently selected from efficacy trials 
in which a trade-off between toxicity and efficacy is evaluated. According to this method 
(referred to as the conventional method) the non-inferiority margin is determined by the size 
of effects that are considered to be of no clinical relevance or to be outweighed by other 
benefits of the experimental treatment (conventional method) [16].  
 
Table 3.2 Summary of possible thresholds of clinical relevance 
Reference Threshold of clinical relevance 
MINDACT Lower boundary of 95% CI of five-year DMFS 
of 92% 
Experts scoping meeting (NVMO) Ten-year OS of 92% (point estimate) 
Experts scoping meeting (NVMO) 3% risk difference in ten-year OS benefit  
IQWiG [12] (One-sided) lower 95% CI for DFS <95% 
PASKWIL criteria (NVMO) [15,16] Five-year OS risk difference >5% or HR<0.7 
(point estimate) 
ESMO-MCBS 3% risk difference in case of mature survival 
data or HR <0.80 (lower boundary of 95% CI) 
in studies without mature survival data 
Tanaka et al. 2012 [14] non-inferiority margins in early breast cancer 
trials varied between HR 1.25 and HR 1.40 (or 
0.60 and 0.75 in case of omitting therapy) 
Abbreviations: DFS: disease-free survival; ESMO-MCBS: European Society for Medical Oncology-
Magnitude of Clinical Benefit Scale; HR: hazard ratio; IQWiG: Institute for Quality and Efficiency in Health 
Care; NMVO: Dutch Association of Medical Oncology; OS: overall survival; PASKWIL: Palliative, adjuvant, 
specific side effects, QoL, impact, and level of evidence; ZINL: National Health Care Institute. 
 
Since this is a European assessment, the European Society for Medical Oncology-Magnitude of 
Clinical Benefit Scale (ESMO-MCBS) clinical relevance thresholds were used [2].  
ESMO has developed ESMO-MCBS, a validated and reproducible tool to assess the magnitude 
of clinical benefit for anti-cancer therapies. The ESMO-MCBS is intended to assist oncologists in 
explaining the likely benefits of a particular treatment to their patients and to help public 
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health decision-makers prioritise therapies for reimbursement. The ESMO-MCBS can be applied 
to comparative outcome studies evaluating the relative benefit of treatments in solid cancers 
using outcomes of survival, treatment toxicity, QoL, or surrogate survival, QoL, or treatment 
outcomes. The ESMO-MCBS has separate evaluation forms: an evaluation form for therapies 
with curative or adjuvant intent, an evaluation form for therapies that are not likely to be 
curative and with primary endpoints other than OS or PFS, and an evaluation form for 
equivalence studies.  
 
Although MINDACT did not adopt a standard non-inferiority design, it relates to an equivalence 
question. For that reason, the evaluation form for equivalence studies (form 2C) is applicable 
to the evaluation of the MammaPrint® [2]. According to ESMO-MCBS criteria for equivalence 
studies, a high level of clinical benefit is proven when reduced toxicity or improved QoL (using 
validated scales) is shown with evidence of statistical non-inferiority or superiority in PFS or 
OS. To determine non-inferiority, a non-inferiority threshold is needed, but there is no 
international consensus on non-inferiority thresholds. For that reason, the GRADE B threshold 
of the ESMO-MCBS (form 1) is used. ESMO describes the highest level of clinical benefit 
(GRADE A) as a survival improvement of >5% at ≥3 years follow-up and a GRADE B survival 
improvement as between 3% and 5%. In the case that mature survival data is not available, 
GRADE A clinical benefit is assigned when DFS improvements are found in which the HR is 
<0.65 and GRADE B clinical benefit is assigned when the HR is between 0.65 and 0.80. In both 
cases, the HR threshold refers to the lower extreme of the 95% CI to take into account 
estimate variability. Since the threshold will be used as a non-inferiority threshold, the 3% 
difference in OS or an HR <0.8 is used here to assess if MammaPrint® is non-inferior in the 
case of ten-year OS (or a surrogate). This 3% difference in ten-year OS was also mentioned in 
the scoping meeting as a minimal important difference. Dutch oncologists (NVMO) consider 
chemotherapy if at least 3% more patients (with similar characteristics) are alive after ten 
years. A smaller benefit does not outweigh the risk of serious toxicity of around 2%. In the 
publication of De Boer et al. [3] it is explained how this consensus of 3% difference was 
achieved [3]. This method in which a trade-off between toxicity and efficacy is one of the 
conventional methods for selecting non-inferiority threshold as mentioned by Tanaka et al 
[14]. Tanaka et al. [14] evaluated non-inferiority trials in early breast cancer where non-
inferiority margins in HR varied between 1.25 and 1.40 (or 0.60 and 0.75 in case of omitting 
therapy). This range approaches the ESMO-MCBS range of 0.65 and 0.80.   
 
3.9 Deviations from project plan 
 
The Scientific Advisory Committee of Zorginstituut Nederland was not included in the current 
EUnetHTA assessment because the Scientific Advice Committee of Zorginstituut Nederland is 
specifically entrusted with assessments for Dutch reimbursement decisions. We instead added 
Prof. dr. P.M.M. Bossuyt as a contributor. Prof. dr. P.M.M. Bossuyt is Professor of Clinical 
Epidemiology with a special interest in methods for evaluating medical tests and markers. Prof. 
dr. P.M.M. Bossuyt is also chairman of the Scientific Advice Committee of Zorginstituut 
Nederland. Dr. S. Lange, MD, employee of IQWiG, was also added as a contributor. 
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4 HEALTH PROBLEM AND CURRENT USE OF TECHNOLOGY 
 
4.1 Research questions 
 
Element ID Research question 
A0002  What is the disease in the scope of this assessment? 
A0007  What is the target population in this assessment? 
A0023  How many people belong to the target population? 
A0005 What are the symptoms and the burden of disease for the patient? 
A0004 What is the natural course of the disease? 
A0006  What are the consequences of the disease for society? 
A0024  How is breast cancer currently diagnosed and staged? 
A0025 How is the breast cancer treatment and risk assessment for adjuvant systemic 
management according to published guidelines and in practice? 
 
4.2 Results 
 
4.2.1 Breast cancer: overview 
Breast cancer is the most frequently diagnosed malignancy in women worldwide. In 2012, the 
estimated age-adjusted annual incidence of breast cancer in 40 European countries was 
94.2/100,000 and mortality was 23.1/100,000 [17]. Breast cancer mortality rates in Europe 
have decreased over the last few decades due to early detection by breast cancer screening, 
improved treatment, and better coordinated clinical pathways [18-20]. Overall, breast cancer 
has a relatively good prognosis, and about 80% of patients with breast cancer are still alive 
ten years after diagnosis. Relative survival depends on tumour stage at the time of diagnosis. 
In women diagnosed with stage I and II breast cancer, overall five-year survival is 87-98% 
and ten-year survival is 78%-94%. In women diagnosed with advanced stage III and IV 
disease, survival rates are 65-85% and 46-76%, respectively [21] (A0002).  
 
Breast cancer may not cause any signs or symptoms in its early stages. Signs and symptoms 
often appear when the tumour grows large enough to be felt as a lump in the breast or when 
the cancer spreads to surrounding tissues or distant parts of the body. However, the disease 
burden is significant and can be quantified in terms of quality-adjusted life years (QALYs) or 
disability-adjusted life years (DALYs), both of which quantify the number of years lost due to 
the disease. In women, breast cancer is sixth in the top ten of diseases with the highest 
burden. Causes of years of healthy life lost to disability include side effects during and after 
treatment (for example, after radiotherapy, chemotherapy, or hormonal therapies), potential 
changes in the menopause, the effects of lymphoedema, and the psychosocial differences in 
“life after therapy”. Most of the disease burden (70%) of breast cancer is caused by premature 
death from breast cancer. Distant metastases account for the majority of breast cancer deaths 
[17] (A0005). 
 
4.2.2 Target population in this assessment 
The target population in this assessment is patients with early breast cancer. Early breast 
cancer is an invasive cancer that is confined to the breast and/or has spread to a limited 
number of axillary lymph nodes but there are no detectable metastases in distant parts of the 
body. Breast cancer tends to be a disease of the older age with about a quarter of breast 
cancers occurring before age 50 and <5% before age 35. The estimated five-year prevalence 
(percentage of patients still alive five years after diagnosis) in Europe in 2012 was 1.8 million 
cases [22]. Ninety per cent were older than 45 years, with the majority (70%) being older 
than 60 years.  
 
Two thirds of breast cancer patients are diagnosed with hormone receptor-positive disease. 
Early-stage breast cancer patients have a good ten-year OS as described above [23]. Hence, 
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preserving QoL and surviving with cancer have become important aims of disease 
management as more patients live long enough to be at risk of long-term side effects from 
treatment and for developing competing causes of morbidity and death such as cardiovascular 
disease (A0007+A0023). 
 
4.2.3 Natural course of early breast cancer 
Despite the good survival rates in the general early breast cancer population, clinicians have 
long recognised heterogeneity in the natural course of the disease and responsiveness to 
cancer therapies [24]. In contrast to locoregional recurrence, distant metastases represent 
virtually incurable disease, as the death rate is close to 100%. There is, however, a complex 
relation between the onset of distant recurrence and the hazard for death due to distant 
recurrence. Late-onset distant metastases, occurring five years or more after primary surgery, 
are often associated with a better prognosis than early-onset distant metastases occurring 
within the first five years after primary surgery [25]. The annual hazard of distant recurrence 
peaks in the second year following primary surgery but remains at 2-5% in years five to 20. 
About a half of all patients with hormone receptor-positive and HER2-negative cancers who 
develop distant recurrences do so after five years [23]. Patients with node-positive disease 
tend to have higher annual hazards of recurrence than patients with node-negative tumours. 
In the first few years following primary treatment, the risk of recurrence is higher in patients 
with ER-negative cancers, but five to eight years after diagnosis, their annual hazard of 
recurrence drops below the level of ER-positive tumours. Breast cancer relapse may occur as 
late as over 20 years after initial diagnosis, particularly in patients with hormone receptor-
positive disease. (A0004). 
 
4.2.4 Diagnosis and staging 
A definitive diagnosis of early breast cancer is provided by histopathological assessment of 
tumour tissue following surgery. Overall, breast cancer diagnosis is based on triple 
assessment: clinical assessment, imaging, and tissue sampling. Histopathological assessment 
of tumour tissue provides information on prognostic factors that might indicate the presence of 
occult metastasis. Independent prognostic factors are tumour size, nodal status, histological 
grade, and lymphatic invasion [24,26]. In addition, immunohistochemical (IHC) detection of 
hormone receptor expression (oestrogen (ER) and progesterone (PR) receptors) and human 
epidermal growth factor receptor 2 (HER2) gene amplification status and protein expression 
are evaluated. As well as being prognostic, these factors predict responses to endocrine and 
HER2-targeting therapies. Proliferation markers such as Ki67 may supply additional useful 
prognostic information [27,28].  
 
In early-stage breast cancer, routine staging evaluations are particularly directed at 
locoregional disease. As distant metastases are very rare in early-stage disease, patients do 
not benefit from comprehensive laboratory (including tumour markers) and radiological staging 
at diagnosis [29]. Current breast cancer staging is based on the TNM (tumour-nodes-
metastasis) system. For breast cancer, the different TNM combinations correspond to five 
stages that indicate tumour burden and disease extent: stage 0 corresponds to carcinoma in 
situ, stage I to III indicate invasive disease with tumour size (T stage) up to 5 cm and/or 
spread of the cancer limited to nearby lymph nodes (N stage); and stage IV corresponds to 
cancer spread to distant tissues and organs (M1 stage: distant metastasis) [30]. Stage I, stage 
IIA, stage IIB, and stage IIIA describe early breast cancer: T1-2 (tumour size 2–5 cm) and 
operable T3 (in case of tumours larger than 5 cm) and N0-1 (disease has spread up to lymph 
nodes) and M0 (no distant metastasis) (A0024). 
 
4.2.5 Treatment of early breast cancer 
The mainstay of early breast cancer management is locoregional treatment of the breast 
through surgery alone or combined with radiotherapy. Optimal management also includes the 
treatment of occult or subclinical metastases (i.e., metastases not detectable at diagnosis) 
with adjuvant systemic therapy. In general, adjuvant systemic therapy will be advised if the 
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estimated absolute ten-year survival benefit is at least 3%. This 3% survival benefit threshold 
is selected since it is considered to be needed to outweigh the incidence of severe toxicity of 
approximately 2% [3]. Adjuvant chemotherapy primarily prevents early metastasis [31-33]. 
However, there is an on-going risk of distant recurrence after five years. This is especially the 
case in ER-positive/HER2-negative breast cancer, where recurrences occur after five years in 
approximately one half of all distant recurrence cases [23]. It is unclear whether these late 
recurrences are prevented by adjuvant chemotherapy. The 2005 Early Breast Cancer Trialists' 
Collaborative Group (EBCTCG) overview [31] stated that the relative benefit of adjuvant 
chemotherapy is similar in all subgroups independent of age, stage, histopathological grade, 
and ER status. However, data from the 2012 EBCTCG overview suggested that the absolute 
benefit is greater for those at high-risk of recurrent disease [33]. As the current assessment 
focuses on adjuvant chemotherapy, neoadjuvant chemotherapy is not discussed further 
(A0025). 
 
Risk assessment and adjuvant chemotherapy planning 
Therapeutic decisions on adjuvant disease management are based on risk estimates. With 
current treatment strategies, up to 30% of women diagnosed with early-stage breast cancer 
will eventually develop metastatic breast cancer, at which point it becomes virtually incurable. 
The death rate from metastatic disease, which is close to 100%, has provided the impetus for 
adjuvant systemic therapy use in early-stage breast cancer. However, the chance of occult 
metastases at the time of diagnosis is not equal in each patient. Approximately 60-70% of 
patients with early breast cancer appear to be free of subclinical metastases at diagnosis and 
do not develop distant metastasis when managed with locoregional treatment alone [1,5]. Risk 
profiling is necessary in order to assign adjuvant chemotherapy to patients most likely to 
benefit from systemic therapy without unnecessarily placing the patient at increased risk of 
treatment side effects (A0025). 
 
Historically, young age, tumour size, and axillary nodal status have been important clinical 
prognostic factors for disease relapse. Larger tumours and a multiple number of positive lymph 
nodes are considered poor prognosis tumours. However, there seems to exist a subgroup of 
patients with small tumours who are at high risk of distant recurrence [24,26]. Likewise, 
patients with a limited number of positive lymph nodes (up to three) may represent a 
subgroup of lymph node-positive women with a low (similar to node-negative) risk of distant 
recurrence [1,31]. The so-called “triple-negative” tumours (ER-, PR-, and HER2-negative) form 
a subgroup with early metastatic capacity. ER-positive tumours are considered to have a more 
indolent prognosis, as they are responsive to hormonal therapy. In addition to being clinically 
heterogeneous, microarray-based gene expression studies have also revealed the significant 
molecular heterogeneity of breast cancer [34-38] (Table A3 in Appendix 1). As a result, 
distinct “intrinsic” molecular breast cancer subtypes can now be recognised within the breast 
cancer spectrum. These subtypes range from tumours with favourable long-term survival 
(luminal A-type breast cancer) to tumours with significantly worse long-term survival (HER2-
positive tumours and basal-like (luminal B often triple-negative) tumours). Each subtype also 
has been shown to be associated with a differential response to treatment with adjuvant 
therapy. It has now become routine practice to tailor treatment regimens to a tumour’s 
molecular signature (i.e. ER and PR status and HER2 status) while also considering traditional 
clinicopathologic characteristics (age, tumour size and tumour grade). Guidelines from 
international scientific societies such as the St. Gallen Breast Cancer Conference, ESMO, and 
the American Society of Clinical Oncology (ASCO) recommend that adjuvant chemotherapy 
should be considered for all patients with early invasive breast cancer after surgery. The 
guidelines underline that the absolute benefit to the individual patient varies substantially 
according to the disease burden and intrinsic tumour biology [39-46]. (Figure A1 in Appendix 
1).  
 
To improve decision-making for adjuvant chemotherapy, the use of prognostic risk 
classification systems such as AO!, and the Nottingham Prognostic Index (NPI) is 
recommended. AO! uses individual patient and pathological data combined with Surveillance, 
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Epidemiology, and End Results Program (SEER) population data to assess baseline risk. Clinical 
trial efficacy data from the EBCTCG is also incorporated into the risk tool to produce age- and 
tumour-specific relative risk estimates and to predict individual treatment benefit from 
chemotherapy [63]. Although these algorithms have been globally investigated, concerns have 
been raised regarding their applicability to populations other than those used in the validation 
studies [46]. Hence, the strength of clinical guideline recommendations and the use of AO and 
the NPI vary across countries (A0025). More recent guidelines from the St Gallen, ESMO and 
ASCO societies recommend on the use of GES tests to guide decision-making for adjuvant 
chemotherapy. These guidelines have been adjusted very recently based on the publication of 
the MINDACT study results (Table A4 in Appendix 1). The strength of the guideline 
recommendations for using GES tests such as MammaPrint® varies in different countries, 
increased use in clinical practice has been observed over time (A0025). 
 
4.2.6 Consequences of the disease for the patient and society 
The consequences of breast cancer and breast cancer treatment include the impact on patient 
well-being during treatment and after completion of treatment. The consequences of morbidity 
and disability associated with breast cancer and its treatment also include the impact on the 
ability of the patient to continue working and include costs associated with treatment and care 
due to morbidity and disability.  
 
Side effects during and shortly after chemotherapy and targeted therapy 
Anthracycline- or taxane-based chemotherapy regimens are current standard adjuvant 
systemic therapy. In addition, HER2-targeted therapy with agents such as trastuzumab may 
be indicated for HER2-positive disease. Chemotherapy and targeted therapy are associated 
with side effects during and shortly after treatment. Common toxic effects of current regimens 
include nausea, vomiting, anorexia, diarrhoea, myelosuppression, febrile neutropenia, 
haemorrhagic cystitis (in schemes using cyclophosphamide), fever and infection, alopecia, 
mucositis, neurotoxicity (taxane-based chemotherapy), amenorrhea (in premenopausal 
women), and serum biochemistry abnormalities. More general symptoms such as anorexia, 
fatigue, and cognitive changes are experienced by patients and have long been observed 
following adjuvant chemotherapy [47]. However, defining standardised and uniform outcome 
measures for these general symptoms has been hampered by methodological limitations. 
 
Late side effects of chemotherapy and targeted therapy 
Chemotherapy is associated with late toxicity, in particular cardiac and haematological toxicity. 
Although the frequency of these toxicities is low, these specific toxicities are serious and 
potentially life threatening [47] (A0006). 
 
Anthracycline cardiotoxicity is well established, particularly at higher cumulative doses. 
Trastuzumab for HER2-positive breast cancer is also an established cardiotoxic agent. The 
frequency of cardiac adverse events is low (<1%), but these events are potentially life 
threatening and the reported cumulative cardiac mortality is 0.6% [48,49]. Sequential and 
non-anthracycline/trastuzumab-based chemotherapy regimens reduce subsequent risk [50]. 
“Late-onset cardiotoxicity” develops following a prolonged asymptomatic period, with heart 
failure presenting one year to decades following chemotherapy. Reassuringly, long-term data 
from these trials suggest that the cumulative cardiac event rate after seven years of follow-up 
is small at 1.7% [43,51]. Still, long-term knowledge on the late effects from anthracyclines in 
otherwise asymptomatic patients is limited. Evidence from cardiology studies in non-cancer 
patients suggests that the presence of asymptomatic left ventricular dysfunction alone 
increases the risk of death and symptomatic congestive heart failure [52]. Despite limited data 
from clinical trials, population-based data from SEER-Medicare showed that older patients have 
a higher risk of cardiac events when treated with anthracycline-based adjuvant chemotherapy. 
Older age, low baseline left ventricular failure, and a history of hypertension are now 
recognised risk factors for cardiotoxicity from anthracycline and/or trastuzumab [53,54] 
(A0006). 
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The risk of developing secondary acute leukaemia was 1-2% at five to ten years follow-up for 
anthracycline, in particular epirubicin-containing regimens [55]. This risk was directly related 
to dose. The National Surgical Adjuvant Breast and Bowel Project (NSABP) reported an eight-
year cumulative incidence of 0.27% for myelodysplastic syndrome (MDS) and/or acute 
myelogenous leukaemia (AML) following treatment with adjuvant doxorubicin and 
cyclophosphamide (AC regimen) [56]. The risk continued to increase beyond five years [55]. 
However, there is little information on the risk of bone marrow neoplasms with non-
anthracycline regimens like docetaxel/cyclophosphamide or docetaxel/capecitabine (A0006). 
 
Health-related quality of life  
Health-related QoL is affected by a complex set of trade-offs between preferences on survival 
benefits and the side effects of adjuvant chemotherapy. It is obvious that the QoL of patients 
receiving adjuvant chemotherapy will be reduced due to chemotherapy side effects during and 
shortly after treatment compared to patients who do not receive chemotherapy. However, 
treatment in the adjuvant setting may provide benefits to the patient other than survival 
benefits. Important drivers behind negative effects on QoL are anxiety, fear of recurrent 
disease, and expectations of the treatment outcome [57-59]. Thus, in addition to the trade-
offs between expected survival benefits and side effects, patient preference for adjuvant 
chemotherapy may have an important impact on health-related QoL. To evaluate the overall 
effect of a medical intervention such as adjuvant chemotherapy, and likewise omitting 
chemotherapy, an outcome measure that combines survival and QoL is necessary. Quality-
adjusted life-years (QALYs), where the quantity of life-years gained is multiplied by a weight 
reflecting the QoL is such an outcome measure. However, relatively few studies have 
estimated health-related QoL for breast cancer patients using preference-based measures in 
the adjuvant setting [60-62]. 
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5 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
 
5.1 Research questions 
 
Element 
ID 
Research question 
B0001 What is Mammaprint® and what is Adjuvant! Online? 
B0002 What is the claimed benefit of MammaPrint® in relation to Adjuvant! Online? 
B0004 Who is involved (prescriber, assessor) in applying the technology? 
A0020 For which indications has MammaPrint® received market authorisation or CE 
marking? 
 
5.2 Results 
 
5.2.1 MammaPrint® 
In an attempt to better understand breast cancer biology and to find new, clinically-relevant 
molecular markers, the Netherlands Cancer Institute (NKI) examined global gene expression 
levels of 78 tumour samples from untreated node-negative breast cancer patients. They used a 
homogenous population of node-negative patients, all under 55 years of age, all treated with 
loco-regional therapy alone, and with a median follow-up of 8.7 years to derive their 
prognostic gene signature. They established a 70-gene expression profile that predicted early 
distant metastases (recurrence within five years) [63,64]. This gene expression profile is called 
MammaPrint®, and it is marketed by Agendia (Amsterdam, the Netherlands; 
http://www.agendia.com). MammaPrint® measures the expression of 70 genes in cancerous 
breast tissue across seven genomic pathways related to metastatic cascade. Each gene is 
weighted equally without influence from clinicopathological factors. The measured expression 
profile is then used in a proprietary algorithm to categorise patients as being at either high of 
low risk of breast cancer recurrence. As its output, MammaPrint® provides a numerical 
MammaPrint® index within the range of -1 to +1. This numerical score is overlaid with a binary 
Low Risk / High Risk clinical classification system. A breast cancer tumour with a MammaPrint® 
index below or equal to zero is classified as High Risk and a tumour with a MammaPrint® index 
higher than zero is classified as Low Risk.” 
 
MammaPrint® is easy to use for the physician. The procedure is as follows: the MammaPrint® 
request can be submitted by a physician via the manufacturer’s online portal. Core needle 
biopsy or surgical specimen samples can be submitted.  
 
Specimen Requirements 
• Formalin-fixed, paraffin-embedded tissue (FFPE): 
o Specimen block with invasive tumour; OR  
o Ten unstained slides with a five-micron section on each slide. 
• Core needle biopsies in RNARetain®. If a 14-gauge needle is used, it is preferable that at 
least three cores are submitted to increase the probability of tumour-positive (30% tumour 
cells) biopsies. To minimise sampling failures, one of the cores selected for MammaPrint® 
should be the first or second core obtained. 
•  At least 30% invasive tumour in the specimen. 
Analysis is performed in one of two central laboratories (the Netherlands and the USA).  
Physicians receive the test results within ten working days, which reports the classification of 
the patient’s cancer as either high risk or low risk. 
 
MammaPrint® validation 
Systematic reviews covering the literature on genetic tests in early breast cancer from 1990 to 
2014 concluded that, of the evaluated tests, Oncotype DX® and MammaPrint® were the 
furthest along their validation pathways (Table A1, Appendix 1). In summary, it was 
concluded that there is no proven benefit from using a GES test. As the vast majority of the 
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currently available evidence is indirect, direct evidence of the clinical utility of GES tests was 
still needed. As the comments of Agendia show there are many publications available that 
provide evidence on test performance, such as analytical validity and the clinical validity.  
 
Claimed benefit of the technology in relation to Adjuvant! Online (B0002) 
The primary claim of MammaPrint® is that it can more reliably identify patients who are at low 
or high risk of distant recurrence, and as such MammaPrint® intends to limit the number of 
patients with side effects by limiting the number of patients receiving chemotherapy. Agendia 
claims that patients defined as low risk by MammaPrint® but who are at high risk according to 
current clinicopathological criteria can safely forgo chemotherapy without deterioration of the 
clinical outcome. By using MammaPrint®, overtreatment can be prevented. Therefore, fewer 
women will be unnecessarily exposed to potential toxicity and chemotherapy side effects, 
thereby improving the overall health and QoL of breast cancer patients. 
 
5.2.2 Adjuvant! Online 
Different countries use different risk stratification tools in standard practice. For example, the 
modified AO!, the NPI, or international clinical guidelines such as those produced by the 
National Comprehensive Cancer Network (NCCN) or St Gallen are used in Europe. In the 
MINDACT study, the modified AO! (which includes HER2 status) was used as the comparator 
risk stratification tool. AO! is a software program (www.adjuvantonline.com) that calculates a 
ten-year survival probability based on the patient’s age, co-morbidities, tumour size, grade, ER 
status and, recently, also HER2 status. The prognostic model is constructed using risk 
estimates based on the observed OS of thousands of breast cancer patients recorded in the 
SEER database, and AO! was validated in over 4000 breast cancer patients from British 
Colombia [65]. In addition, AO! calculates the absolute survival benefit of any proposed 
adjuvant therapy by using treatment effect estimates from meta-analyses and RCTs to 
proportionately adjust its mortality and recurrence rates. Access to AO! is currently disabled 
because it is being updated to reflect the most recent data. Physicians currently depend on 
using other guidelines with varying recommendations such as PREDICT. In November 2016, 
AO! and PREDICT risk models were both endorsed by the American Joint Committee on Cancer 
for their use in routine practice (AJCC Cancer Staging Manual, 8th edition of TNM classification) 
[40,66]. 
 
5.2.3 Features of the technology and comparators 
The features of the technology and comparators are summarised in Table 5.1. 
 
Table 5.1 Features of the intervention and comparators 
 Technology 
 
Comparator 
 
Name MammaPrint® Modified Adjuvant! Online 
Proprietary name MammaPrint® Modified Adjuvant! Online 
Manufacturer Agendia Adjuvant Inc. 
Names in other countries Not applicable Not applicable 
Class / GMDN code In vitro Diagnostic Directive  
GMDN code: 60943 
Not applicable 
 
5.2.4 Marketing authorisation or CE-marking (A0020) 
CE marking 
In May 2005, Agendia received CE marking for MammaPrint® in accordance with the CE 
guidelines for a medical device for in vitro diagnostics (directive 98/79/EG) [67]. CE marking 
was given for both fresh frozen tissue and FFPE tissue. The intended use for which the CE 
marking was given is: MammaPrint® is a qualitative in vitro diagnostic test, performed in a 
central Agendia laboratory, using the gene expression profile from FFPE breast cancer tissue 
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samples to assess a patient’s risk of distant metastasis. The test is performed on tissue from 
breast cancer patients with stage I or stage II disease, tumour size ≤5.0 cm, lymph node 
negative or with up to three positive lymph nodes. 
 
FDA status 
The US Food and Drug Administration (FDA) gave In Vitro Diagnostic Multivariate Index Assay 
(IVDMIA) clearance for MammaPrint® in 2007. It was the first cleared molecular test to profile 
genetic activity. The MammaPrint® test is a laboratory-developed test which falls into the class 
of IVDMIA. MammaPrint® FFPE received a Predicate Device 510(k) clearance in 2015. The FDA 
label indicates that MammaPrint® and MammaPrint® FFPE can be used as a prognostic risk 
stratification tool for early-stage breast cancer patients. The FDA cleared MammaPrint® for 
marketing with the intended use: MammaPrint® (FFPE and fresh-frozen tissue) is a qualitative 
in vitro diagnostic test, performed in a central laboratory, using the gene expression profile 
obtained from FFPE breast cancer tissue samples or fresh breast cancer tissue to assess a 
patient’s risk for distant metastasis within 5 years (FFPE) or up to ten years for patients less 
than 61 years old, up to 5 years for patients ≥61 years (fresh breast cancer tissue). The genes 
and scoring algorithm for MammaPrint® FFPE are the same as those used for MammaPrint®, 
performed with fresh and fresh-frozen tissues. The test is performed for breast cancer 
patients, with Stage I or Stage II disease, with tumour size ≤ 5.0 cm and lymph node 
negative. The MammaPrint® FFPE result is indicated for use by physicians as a prognostic 
marker only, along with other clinicopathological factors. FDA formulated the following special 
conditions for use statement(s): MammaPrint® FFPE is not indicated as a standalone test to 
determine the outcome of disease, nor to suggest or infer an individual patient’s likely 
response to therapy. Results should be taken in the context of other relevant 
clinicopathological factors and standard practice of medicine [68]. 
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6 CLINICAL UTILITY  
 
6.1 Research questions 
 
Element ID Research question 
D0001 What is the expected effect of the intervention on mortality? 
D0032 How does the test-treatment intervention modify the magnitude and 
frequency of morbidity? 
D0011  What is the effect of MammaPrint® and treatment on patients’ body 
functions? 
D0016  How does MammaPrint® use and treatment affect activities of daily living? 
D0012 What is the effect of MammaPrint® and treatment on generic health-
related quality of life? 
D0013 What is the effect of MammaPrint® and treatment on disease-specific 
quality of life? 
C0008 How safe is the technology in relation to the comparator(s)?  
C0004  What are the advantages of not receiving chemotherapy (what harms 
were prevented)? 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of MammaPrint®?  
C0006 What are the consequences of false-positive, false-negative, and 
incidental findings generated by using the technology from the patient 
safety viewpoint?  
D0017  How many patients follow the treatment advice based on the 
MammaPrint® result? 
 
6.2 Results 
 
In collaborative EUnetHTA reports, clinical effectiveness and safety outcomes are usually 
reported in two separate chapters. However, because we are primarily interested in the clinical 
utility of MammaPrint® all critical endpoints (OS, QoL, and short- and long-term side effects of 
chemotherapy) are reported in the same section. The critical endpoint of OS is in fact the 
safety endpoint in this assessment.  
 
6.2.1 Included studies 
Direct evidence of the clinical utility of the 70-gene signature test MammaPrint® was available 
from one RCT (MINDACT) [4]. A description of the evidence used is provided in Section 3.6. 
 
6.2.2 Study characteristics 
 
6.2.2.1 Study design  
The MINDACT study is an international, open-label, randomised controlled, phase 3 trial in 
women with early-stage breast cancer (n=6693, median follow-up five years). MINDACT 
compares the MammaPrint® 70-gene signature test added to standard clinicopathological 
criteria with current clinicopathological risk assignment based on AO!,( using a modified 
version) in selecting patients for adjuvant chemotherapy. MINDACT was supported by several 
grants as described in Table 3.1. Between 2007 and 2011, 6693 patients were enrolled in 112 
institutions in nine European countries. Eligible patients were women between 18 and 70 years 
of age with histologically-confirmed primary invasive breast cancer (stage T1, T2, or operable 
T3). The primary objective of MINDACT was to assess whether, in patients with a high clinical 
risk and a low genomic risk (CH/GL) in whom chemotherapy was omitted, the lower boundary 
of the 95% CI for the rate of five-year DMFS would be 92% (i.e., the non-inferiority boundary) 
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or higher at a one-sided significance of 0.025.  
 
As a starting point for determining the non-inferiority threshold in MINDACT, there was 
consensus in the TRANSBIG Consortium 2014 (a 21-country network associated with the 
Breast International Group (BIG)) that for every hundred women spared chemotherapy, eight 
patients will still be at risk and develop metastatic disease. The non-inferiority threshold was 
derived from a ten-year breast cancer survival probability using AO! (version 7) of 92% for ER-
negative tumours to account for the estimated four percentage point absolute benefit from 
adjuvant endocrine therapy in ER-positive tumours [55,69]. The 4% gain in survival is the 
benefit that is needed to counterbalance the 2% risk of severe adverse events associated with 
adjuvant chemotherapy [50,51,55,56]. The TRANSBIG consortium subsequently reached a 
consensus on a threshold for non-inferiority of 92% at five years (DMFS).   
 
MINDACT’s main characteristics are described in Table 3.1 and Table A.5 (Appendix 1).  
 
Protocol revisions 
• In the first version (January 2006) of the protocol, the primary objective of MINDACT was to 
demonstrate the superiority of the molecular profiling approach over usual clinical 
assessment in assigning adequate risk categories (and the need to receive adjuvant 
chemotherapy or not) to node-negative breast cancer patients [63]. In July 2006, the 
EORTC published a revision of the primary objective: the primary objective of MINDACT 
was to confirm that patients with a “low risk” molecular prognosis and “high risk” clinical 
prognosis can be safely spared chemotherapy without affecting DMFS.  
• In August 2009, the protocol was revised to allow enrolment of women with up to three 
positive axillary nodes instead of only lymph node-negative patients. 
• A change in the RNA extraction solution used in the assay caused a temporary shift in the 
risk calculation. This shift resulted in 162 patients originally identified as being at high 
genomic risk subsequently being reclassified as low genomic risk with the use of the 
correct solution. The clinical effect of this risk revision was that an additional 28 patients 
received chemotherapy before the results were corrected, although no patient was 
undertreated. 
• The sample size was modified during the trial from 6000 to 6600 patients, because the 
proportion of patients designated as low clinical and genomic risk was higher than initially 
projected because of the need to compensate for the change in RNA extraction solution.  
 
6.2.2.2 Study patients 
A total of 11288 patients underwent screening, and 6693 patients were enrolled in the study. 
Of the 4595 patients (40.7%) who were not enrolled, the main reasons were the unsuitability 
of tumour material for testing (n=1182; 26%) and a decision by the patient or an investigator 
not to participate in the study (n=899; 20%). Other reasons for non-enrolment are presented 
in Table A7  in Appendix 1. There were four main groups (corresponding to corrected risk): 
low clinical and low genomic risk (CL/GL; n=2745; 41%); low clinical and high genomic risk 
(CL/GH; n=592; 8.8%); high clinical and low genomic risk (CH/GL; n=1550; 23.2%); and high 
clinical and high genomic risk (CH/GH; n=1806; 27%). The median age of the patients was 55 
years (range 23-71); 79% had node-negative disease, and 20.9% had one to three positive 
nodes. 88.4% of tumours expressed ER, PR, or both, and 9.5% were HER2-positive. Baseline 
characteristics are presented in Table A2 in Appendix 1. 
 
6.2.2.3 Study adherence  
In the discordant risk groups in the MINDACT trial, overall adherence to chemotherapy 
assignment was 86%. In CH/GL patients, the adherence rate was 85% in those in the 
chemotherapy group and 89% in those in the no-chemotherapy group. In CL/GH patients, 
adherence rates were 80% and 88%, respectively (D0017). 
 
6.2.3  Quality of the study  
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Different scientific societies and individual countries use different clinical relevance thresholds. 
As described in Section 3.8.1, the ESMO-MCBS threshold of HR 0.80 to determine imprecision 
in GRADE is used. This HR threshold refers to the lower extreme of the 95% CI.  
 
6.2.3.1 Risk of bias 
The risk of bias was rated as high at the study level for the CH/GL population due to the 
considerable number of patients who were not treated as assigned by randomisation. Of the 
patients randomised to chemotherapy (n=749), 174 (23%) were not included in the PP 
analysis (of whom 128 did not receive chemotherapy, 26 had a change in risk, 11 were 
ineligible, and nine had an unknown chemotherapy status). Of those assigned to no 
chemotherapy (n=748), 119 (16%) were not included in the PP analysis (of whom 85 received 
chemotherapy, 21 had a change in risk, 12 were ineligible, and one had an unknown 
chemotherapy status). However, the baseline patient characteristics of the randomised groups 
in the PP population were not presented. Therefore, no information could be obtained to assess 
comparability of baseline characteristics. Additionally, no lost-to-follow-up data was reported 
and it was an open-label study. The risk of bias for the CL/GH population was low. Although 
MINDACT was an open-label study, we found downgrading only for this too strict, because the 
OS, DMFS, and DFS are objective outcome measures. The risk of bias of the study and the 
different outcome measures are reported in Table A9 and Table A10 in Appendix 1.  
 
6.2.3.2 GRADE  
The complete GRADE summary of finding tables of both discordant groups are included as 
Table A11 and Table A12 in Appendix 1.  
 
Clinical high and genomic low (CH/GL) 
The quality of the evidence for the CH/GL population for the critical endpoint of ten-year OS 
was rated as low (with DMFS and DFS used as surrogates) to very low (when direct 
measurements of OS but only five-year data was used), due to the risk of bias (see Table A9 
and Table A10 in Appendix 1), indirectness (use of a surrogate outcome/follow-up), and 
imprecision (CIs crossing one or two thresholds of clinical relevance). Therefore, confidence in 
the OS effect estimate after ten years is limited at best, and the true effect may be 
substantially different from the effect estimate.  
 
Clinical low and genomic high (CL/GH) 
The quality of the evidence for the CL/GH population for the critical endpoint of ten-year OS 
was rated very low (for both DMFS and DFS surrogate endpoints and also the direct 
measurement of OS, but only five-year follow-up data was used) due to the risk of bias (see 
Table A9 and Table A10 in Appendix 1), indirectness (use of a surrogate outcome), and 
imprecision (CIs crossing both thresholds of clinical relevance). Therefore, there is very little 
confidence in the effect estimate, and the true effect is likely to be substantially different from 
the effect estimate.  
 
6.2.4 Results of the primary EUnetHTA assessment: clinical utility in the CH/GL risk group 
From a reimbursement perspective, a diagnostic test added to standard care must have proven 
added value in health-related outcomes compared to standard care alone. MINDACT’s first pre-
specified secondary analysis specifically addressed the main EUnetHTA research question. In 
the case of the CH/GL population, the added value will not be in terms of survival, as 
MINDACT’s primary objective is not superiority but to safely spare chemotherapy in this group 
(non-inferiority in term of OS). The added value is that patients will potentially experience a 
better QoL(superiority in terms of QoL and toxicity). 
 
6.2.4.1 Overall survival  
 
Surrogate endpoints for ten-year OS 
Data on ten-year OS is not yet available, so surrogate endpoints were considered. First the 
relation between the surrogate endpoints and the critical endpoint is described. In MINDACT, 
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the primary endpoint was five-year DMFS as assessed in the time-to-event analyses. Other 
reported endpoints were five-year OS and five-year DFS. The DMFS definition was the time 
until the first distant metastatic recurrence or death from any cause. The DFS definition was 
the time until first disease progression (locoregional, distant relapse, ipsilateral or contralateral 
invasive breast cancer, ductal carcinoma in situ, or a second invasive primary cancer) or death 
from any cause. DFS also takes into account locoregional recurrences, which still can be 
treated with curative intent. Regarding the relation between five-year DMFS and ten-year OS, 
it is known that if distant metastases occur, two out of three women will die of cancer within 
ten years [11]. For this reason, DMFS after five years predicts the threat to patient survival 
and so is a surrogate for OS after ten years [70]. However, the relation between ten-year OS 
and five-year DMFS is not one-on-one. The benefit of adjuvant chemotherapy is primarily 
limited to reducing recurrences within the first five years. However, there is an on-going risk of 
distant recurrence after five years. Another frequently used surrogate for ten-year OS is five-
year DFS. DFS is a widely accepted surrogate for OS in adjuvant cancer treatments, for 
example in the European Medicines Agency (EMA) and FDA scientific guidelines. Furthermore, 
it is a relevant outcome measure for patients, because any recurrence discovered during 
follow-up (regardless of whether it is curable or not) is a relevant event for a patient [59]. Also 
for DFS applies that the relation between five-year DFS and ten-year OS is not one-on-one. In 
this report the results of five-year DMFS, five-year DFS and five-year OS are reported, because 
it is possible that different countries will choose different surrogate endpoints for ten-year OS 
(Table 6.1 and Figure 6.1).  
 
PPS versus PP population 
Due to the temporary change in risk assessment between May 24, 2009 and January 30, 2010 
(as a result of assay problems), all risk groups as enrolled in that particular period are 
somewhat biased due to incorrect risk assessment. Next to the prespecified PP analysis, also 
so-called PPS analysis is presented in the MINDACT publication, in which all patients enrolled 
during the period of change in risk were excluded. This PPS analysis is less biased as the 
legend of table S5 of the MINDACT publication confirms. This PPS analysis is presented as 
sensitivity analysis, but in fact this PPS analysis represents the least biased and therefore most 
conservative PP analysis. Therefore, the results of this PPS population are described in this 
section. For the sake of completeness the results of the PPS, PP and the ITT analyses are 
presented in Table 6.1.  
 
Results of surrogate endpoints for ten-year OS 
The CH/GL patients in the PPS analysis who received chemotherapy after randomisation on the 
basis of clinical risk had a five-year DMFS rate of 96.5% (95% CI 94.1-97.9), whereas those 
who did not receive chemotherapy (randomly assigned on the basis of genomic risk) had a rate 
of 94.0% (95% CI 91.4-95.8), a 2.5% lower rate (HR 0.60; 95% CI 0.34-1.06; p=0.080). 
Expressed in absolute numbers, omitting chemotherapy after following MammaPrint® risk 
assessment and not AO! can lead to 100 (of 1000) more patients that will not be free of 
distant metastases after five years. Looking at the 95% CI of five-year DMFS, it could lead to 
six less or at worst 287 more patients who are not free of distant metastases after five years 
(see Table A11, Appendix 1). Five-year DFS of those who received chemotherapy based on 
clinical risk was 93.3% (95% CI 90.3-95.4), whereas those who did not receive chemotherapy 
based on genomic risk had a 4.5% lower rate of 88.8% (95% CI 85.7-91.3). Although the 
study was not powered to assess statistical differences, the adjusted HR of 0.57 (95% CI 0.37-
0.87; p=0.009) was statistical significant. The five-year OS was 1.8% higher in the AO! 
treated patients with a HR of 0.54 (95% CI 0.23-1.26), but this difference was not significantly 
different (p=0.154). The 95% CIs of five-year DMFS and five-year OS crossed the non-
inferiority threshold of HR 0.80, indicating non-inferiority of MammaPrint® is questionable (like 
the blue line in Figure 3.2). However, the point estimates are on the left side of the non-
inferiority threshold (like the red line in Figure 3.2). It is therefore reasonable to assume that 
using MammaPrint® may result in an increased risk of death in comparison with AO! risk 
assignment (see green line and orange line in Table 6.1). Because the difference in five-year 
DFS is statistically significant different, inferiority is likely but non-inferiority cannot be ruled 
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out either (like the red line in Figure 3.2 and see the blue line in Table 6.1). For those HTA-
organisations that use risk differences in their assessment the same conclusion can be made. 
The risk differences are 2.5% for five-year DMFS and 4.5% for five-year DFS and 1.8% for 
five-year OS. The risk difference of five-year DFS (4.5%) crosses the non-inferiority threshold 
of 3%. Those of DMFS and OS do not cross the non-inferiority threshold, but since in general 
the confidence intervals are large, it is reasonable to assume that also for five-year DMFS and 
five-year OS the required non-inferiority is not shown.  
 
As described above, the five-year DFS for treatment decisions based on clinical risk 
(chemotherapy) and treatment decisions based on MammaPrint® (no chemotherapy) was 
significantly worse (p=0.009) for MammaPrint® patients. The lower limit of the 95% CI of 0.37 
was <0.65, making this difference GRADE A according to ESMO-MCBS criteria and indicating 
substantial inferiority for those patients in whom the treatment decision was based on 
MammaPrint®.  
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Table 6.1 Summary of the results of the surrogate OS endpoints for CH/GL patients  
 Patients  
(n) 
 
 HR (95% CI, p-value) Absolute benefit between 
treatment based on AO! 
(receiving chemotherapy) and 
treatment based on 
MammaPrint® (omitting 
chemotherapy)** 
PPS* 1045 OS: 0.54 (0.23-1.26, 
p=0.154) 
DFS: 0.57 (0.37-0.87, 
p=0.009) 
DMFS: 0.60 (0.34-1.06, 
p=0.080) 
OS: -1.8% 
DFS: -4.5% 
DMFS: -2.5% 
 
PP 1228 OS: 0.63 (0.29-1.37, p=0.25) 
DFS: 0.64 (0.43-0.95, 
p=0.03) 
DMFS: 0.65 (0.38-1.10, 
p=0.11) 
 
OS: -1.5% 
DFS: -3.0% 
DMFS: -1.9% 
ITT 1497 OS: 0.69 (0.35-1.35, 
p=0.278) 
DFS: 0.71 (0.50-1.01, 
p=0.055) 
DMFS: 0.78 (0.50-1.21, 
p=0.267) 
 
OS: -1.5% 
DFS: -1.9% 
DMFS: -1.4% 
 
Abbreviations: AO!: Adjuvant! Online; DFS: disease-free survival; DMFS: distant metastasis-free 
survival; HR: hazard ratio; ITT: intention to treat population; OS: overall survival; PP: per protocol; PPS: 
per protocol sensitivity. 
* The PPS population is the PP population but with all patients enrolled between May 24 2009 and January 
30 2010 excluded. 
** A minus refers to a benefit of risk assignment based on the AO risk score. 
   
Figure 6.1 Results in the CH/GL risk patients in relation the non-inferiority threshold 
 
 
Abbreviations: DFS: disease-free survival (including CI’s); DMFS: distant metastasis-free survival 
(including CI’s); HR: hazard ratio; OS: overall survival (including CI’s). 
*1 = non-inferiority threshold of HR 0.80. 
 
6.2.4.2 Quality of life 
A better QoL was the expected advantage for patients not receiving chemotherapy based on 
the MammaPrint® result. However, in MINDACT, long-term modifications in morbidity such as 
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improved QoL, fatigue, or physical functioning were not measured. However, long-term QoL is 
not directly measured in the MINDACT trial, it may be argued that some aspects of QoL are 
reflected by other outcomes. As mentioned in Section 4.2.6 it is obvious that the QoL of 
patients receiving adjuvant chemotherapy will be reduced due to chemotherapy side effects 
during and shortly after treatment compared to patients who do not receive chemotherapy. 
This benefit in quality of life during the administration period chemotherapy is indirectly known 
from empirical evidence. In addition, the MINDACT study shows that refraining from 
chemotherapy leads to a significant and clinically relevant worse five-year DFS. Nearly all 
types of recurrences are stressful to patients even in the case of a curable disease. This 
distress will have its repercussions on quality of life. Because QoL is not available in the 
MINDACT, the added value of the MammaPrint® in terms of QoL in the long term cannot be 
quantified.  
 
6.2.4.3 Short- and long-term side effects of chemotherapy 
Fewer short- and long-term side effects were expected as an advantage of not receiving 
chemotherapy for patients not receiving chemotherapy based on the MammaPrint® result. 
Short- and long-term side effects were measured in the MINDACT trial but not published in 
Cardoso et al [4]. However, it is known that chemotherapy complications include leukaemia, 
cardiovascular disease, and other side effects as described in Section 4.2.6.  
 
Supportive evidence on clinical utility 
As described in Section 3.6, a description of prospective studies relevant to clinical utility 
question was permitted when only one RCT was found. However, no controlled observational 
studies that provided evidence on clinical utility were found.    
 
6.2.5 Results of the secondary analyses 
 
Clinical low risk and genomic high risk (CL/GH) 
Ten-year OS (surrogates: five-year DMFS, five-year DFS, and five-year OS) 
Ten-year OS data is not yet available, so here five-year DMFS, five-year DFS, and five-year OS 
as surrogates are reported (Table 6.2 and Figure 6.2). In this case, adjuvant chemotherapy 
is given based on the MammaPrint® result to patients that would not usually receive 
chemotherapy based on their clinical risk, so an OS effect would represent the added value. 
Therefore, ITT population data is presented. CL/GH patients who after randomisation received 
chemotherapy on the basis of genomic risk had a five-year DMFS rate of 95.8% (95% CI 92.9-
97.6), whereas those not receiving chemotherapy (randomly assigned based on clinical risk) 
had a 0.8% lower five-year DMFS rate of 95.0% (95% CI 91.8-97.0). However, this difference 
was not statistically significant (p=0.657). 
 
The five-year DFS surrogate endpoint was 92.1% (95% CI 88.3-94.6) for patients who 
received chemotherapy (on the basis of genomic risk) and 90.1% (95% CI 86.1-93.0) for 
patients who did not receive chemotherapy (based on clinical risk), 2.0% lower than the rate 
among those who received chemotherapy based on the MammaPrint® result (p=0.603). For 
five-year OS, 97.1% (95% CI 94.5-98.5) of patients who received chemotherapy (based on 
genomic risk) and 97.8% (95% CI 95.5-99.0) of patients who did not receive chemotherapy 
(based on clinical risk) were still alive, 0.7% lower in those who received chemotherapy based 
on the MammaPrint® result (p=0.578). None of the surrogate endpoint differences were 
significant, and added value of MammaPrint® has not been demonstrated at this time.c 
However, the study was not powered to assess significant differences in this discordant group, 
so a clinical benefit for MammaPrint®-based treatment decision-making cannot be ruled out. 
 
  
                                               
c We did not report the HRs of OS and DFS because the HRs do not correspond with the % at five-year DFS and OS. 
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Table 6.2 Summary of the results of the surrogate endpoints for the CL/GH patients 
 Patients  
(n) 
 
HR (95% CI, p-value) Absolute benefit between 
treatment based on 
MammaPrint® (receiving 
chemotherapy) and 
treatment based on AO! 
(omitting chemotherapy)**  
ITT 1497 OS: 1.28 (0.54-3.02, 
p=0.578) 
DFS: 0.87 (0.53-1.45, 
p=0.603) 
DMFS: 1.17 (0.59-2.28, 
p=0.657) 
OS: -0.7% 
DFS: 2.0% 
DMFS: 0.8% 
Abbreviations: AO!: Adjuvant! Online; DFS: disease-free survival; DMFS: distant metastasis-free 
survival; HR: hazard ratio; ITT: intention to treat population; OS: overall survival. 
** A minus refers to a benefit of risk assignment based on the AO! risk score, where above zero refers to 
that risk assignment based on MammaPrint® leading to a benefit. 
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Figure 6.2 Results in the CL/GH risk patients in relation to threshold for clinical 
relevance 
 
 
 
Abbreviations: DFS: disease-free survival; DMFS: distant metastasis-free survival; HR: hazard ratio; OS: 
overall survival. 
*1 = HR 0.80 and HR 1.20 are the thresholds for clinical relevance. 
 
MammaPrint® used instead of Adjuvant! Online 
Outcomes were also assessed in all patients if chemotherapy use had been guided by either 
clinical risk or genomic risk assignment alone. This is especially relevant for countries where 
prognostic models such as AO! are not widely accepted, for example if external validation is 
not available. 
 
50.1% of all patients had a high clinical risk (3356/6693), of whom 1550 had a low genomic 
risk and 1806 had a high genomic risk. 35.8% (2398/6693) of patients were categorised as 
being high genomic risk (592 with a low clinical risk and 1806 with a high clinical risk). Thus, 
the difference between the two strategies for chemotherapy administration would be 14.3% 
(958 patients). Among all patients at high clinical risk, the use of MammaPrint® to guide 
chemotherapy treatment would lead to a reduction in the use of adjuvant chemotherapy in 
1550 of 3356 patients (46.2%).  MINDACT also estimated the outcomes in all patients if 
chemotherapy use had been recommended by either clinical risk or genomic risk alone. To 
obtain an unbiased estimate, the discordant patients were doubly weighted because they were 
underrepresented by a factor of two. Comparison by means of classical statistical inference 
would be incorrect, so MINDACT only showed the estimated five-year DMFS. At five years, the 
DMFS would have been 95.0% with the clinical risk strategy alone and 94.7% with the 
genomic risk strategy alone. The results are presented in Table A16 in Appendix 1.  
 
6.2.6 Results of the pre-specified subgroup analyses 
MINDACT also reports exploratory the results of pre-specified subgroups (nodal status, T 
status, HR+/HER2-LN0). The results of these subgroups are described below. The study 
authors reported the DMFS after five years only for the ITT population. These subgroup 
analyses are underpowered, so no definitive conclusions can be made. 
 
Nodal status (CH/GL, ITT population) 
For the subgroup of CH/GL patients with lymph node-negative (LN0) status, DMFS was 95.7% 
(95% CI 93.0-97.4) when the clinical risk profile was followed (chemotherapy) (n=395) and 
93.2% (95% CI 90.1-95.4) when genomic risk was followed (no chemotherapy) (n=392). The 
HR was 0.69 (95% CI 0.39-1.21) (p=0.193). 
 
For the lymph node-positive subgroup, the DMFS was 96.3% (95% CI 93.1–98.1) when clinical 
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risk was used (chemotherapy) (n=353) and 95.6% (95% CI 92.7-97.4) when genomic risk 
was used (no chemotherapy) (n=356). The HR was 0.88 (95% CI 0.42-1.82) (p=0.724). 
 
Nodal status (CL/GH, ITT population) 
For the subgroup of CL/GH patients with lymph node-negative disease who did not receive 
(using clinical risk) chemotherapy (n=333), DMFS was 95.1% (95% CI 91.9-97.1) and, for 
those who received chemotherapy (based on their genomic risk) (n=333), the DMFS was 
96.0% (95% CI 93.1-97.7). This difference of 0.9% was not statistically significant (p=0.815). 
The HR was 1.09 (95% CI 0.54-2.19). 
 
The lymph node-positive group (CL/GH) was too small for analysis. 
 
Tumour size (CH/GL, ITT population) 
For the subgroup of CH/GL patients with a tumour larger than 2 cm but no larger than 5 cm 
(T2), DMFS was 94.5% (95% CI 91.4-96.6) when the clinical risk profile was followed 
(chemotherapy) (n=402) and 93.7% (95% CI 90.6-95.8) when the genomic risk was followed 
(no chemotherapy) (n=406). This difference of 0.8% was not statistically significant 
(p=0.706). The HR was 0.90 (95% CI 0.53-1.54). 
 
For the subgroup of CH/GL patients with a tumour smaller than 2 cm (T1), DMFS was 97.6% 
(95% CI 95.1–98.9) when clinical risk was used (chemotherapy) (n=322) and 94.8% (95% CI 
91.5-96.8) when genomic risk was used (no chemotherapy) (n=314). This difference of 2.8% 
was not statistically significant (p=0.201). The HR was 0.59 (95% CI 0.26-1.33). 
 
Tumour size (CL/GH, ITT population) 
For the subgroup of CL/GH patients with a tumour smaller than 2 cm (T1), DMFS was 94.9% 
(95% CI 91.6-96.9) when the clinical risk profile was followed (no chemotherapy) (n=338) and 
95.7% (95% CI 92.6-97.5) when genomic risk was followed (chemotherapy) (n=333). This 
difference of 0.8% was not statistically significant (p=0.851). The HR was 1.07 (95% CI 0.54-
2.12). 
 
The subgroup of CL/GH patients with T2 tumours was too small to be analysed. 
 
HR+/HER2-/LN0 (CH/GL, ITT population) 
For the subgroup of CH/GL patients with hormone receptor-positive (HR+), human epidermal 
growth factor receptor 2 negative (HER2-) and lymph node-negative (LN0) status, the DMFS 
was 95.5% (95% CI 92.5-97.3) when the clinical risk profile was followed (chemotherapy) 
(n=349) and 93.9% (95% CI 90.6-96.1) when genomic risk was followed (no chemotherapy) 
(n=350). This difference of 1.6% was not statistically significant (p=0.456). The HR was 0.80 
(95% CI 0.44-1.45). 
 
HR-/HER2+/LN0 (CL/GH, ITT population) 
For the subgroup of CL/GH patients with hormone receptor-negative (HR-), human epidermal 
growth factor receptor 2 positive (HER2+) and lymph node-negative (LN0) status, the DMFS 
was 95.5% (95% CI 91.6-97.6) when the clinical risk profile was followed (no chemotherapy) 
(n=262) and 95.1% (95% CI 91.5-97.2) when genomic risk was followed (chemotherapy) 
(n=272). This difference of 0.4% was not statistically significant (p=0.333). The HR was 1.45 
(95% CI 0.68-3.08). 
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7 DISCUSSION 
 
From a reimbursement perspective, a diagnostic test added to standard care must have proven 
added value in health-related outcomes compared to standard care alone. It has been claimed 
that MammaPrint® has a substantial, positive effect on the health and well-being of women 
with early breast cancer by limiting the number of patients receiving adjuvant chemotherapy 
and, as a consequence, related adverse events, without negatively affecting overall survival. 
For this purpose, the MINDACT authors predefined a non-inferiority threshold as the cut-off for 
the benefit of using MammaPrint® for the decision of administering chemotherapy: among 
CH/GL patients who did not receive chemotherapy, the lower boundary of the CI of the five-
year DMFS should be 92% or higher.  
 
According to the MINDACT study authors, five-year DMFS was not negatively affected in the 
primary test population of women with the CH/GL risk profile when the genomic profile 
(MammaPrint®) was followed. However, our assessment concludes that the current data is 
insufficient to determine that it is safe to omit chemotherapy and insufficient to determine that 
there is added value in the CH/GL population of early breast cancer patients. Our reasoning is 
as follows.  
 
7.1 Non-inferiority threshold and magnitude of clinical relevance 
 
From a reimbursement perspective, it is necessary that new and standard approaches are 
compared because added value must be proven when a test or intervention is added to 
standard care. Also, the IQWiG concluded that the risk of distant metastases in women in the 
groups with and without chemotherapy should have been compared instead of evaluating only 
one arm. Bogaerts et al. [69] mentioned this issue as a major criticism of the primary analysis 
of MINDACT. Despite the aim to prove non-inferiority for the five-year DMFS endpoint, 
MINDACT does not have a formal non-inferiority design, and a trial with a non-inferiority 
design would need to be very large or of extremely long duration. Bogaerts et al. [69] 
proposed that if the primary test is significant and the gene signature selects fewer patients to 
be treated with chemotherapy while not adversely affecting five-year DMFS, then this can be 
taken as equivalent to proving that the signature has very good sensitivity and a specificity 
that is better than the clinicopathological method.  
 
This assumption would be acceptable in the situation that the five-year DMFS of the CH/GL 
subgroup who received chemotherapy was reliably known. However, this subgroup could not 
be selected from the SEER database. Since this information was not available at the start of 
the MINDACT study and a threshold had to be prespecified, the TRANSBIG consortium 
members decided on a non-inferiority threshold of 92% derived from a ten-year breast cancer 
survival probability using Adjuvant! Online. This choice of non-inferiority threshold is rational. 
However, different thresholds could have been chosen as decisions with respect to the use of 
adjuvant chemotherapy are subjective and highly variable among patients, physicians, 
scientific and HTA-organisations. In their comment on MINDACT, Thewes et al. [71] suggested 
that most patients with breast cancer are willing to accept adjuvant chemotherapy for very 
small survival gains (≤1%). Hamelinck et al. [72] also concluded that most patients judged 
small to moderate benefits sufficient to consider adjuvant systemic therapy worthwhile, but 
individual preferences varied widely. Taken together, the 92% five-year DMFS non-inferiority 
boundary of the MINDACT trial can be regarded as unconventional. Furthermore, the lower 
boundary of the 95% CI of the PPS population was 91.4%, which is below the non-inferiority 
threshold of 92% defined by the MINDACT authors. The PPS population provides the least 
biased and most conservative estimate of OS. 
 
The question remains which threshold should instead be used to determine if omitting 
chemotherapy is safe. Because the five-year DMFS of the CH/GL subgroup who received 
chemotherapy was not reliably known, a direct comparison between the two arms is needed. 
Overall, there is no consensus what non-inferiority threshold should be used to determine 
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when a difference between the two arms is unacceptable. Since this is a European assessment, 
the ESMO-MCBS clinical relevance thresholds were used [2]. Based on the ESMO-MCBS, a non-
inferiority threshold of HR 0.80 or a risk difference of 3% is used. It can be argued that these 
criteria were primarily intended to stratify the magnitude of clinical benefit that can be 
anticipated from anticancer therapies. However, this conventional method of selecting a non-
inferiority threshold is often used as concluded by Tanaka et al [14] and in accordance with 
non-inferiority thresholds used in non-inferiority trials in early breast cancer. In addition, even 
though MammaPrint® is a diagnostic test, the added value of the ‘test plus treatment’ on 
health related outcomes needs to be proven. 
 
In the first prespecified secondary MINDACT analyses, outcomes were compared in patients in 
the discordant risk groups according to whether they were assigned to the chemotherapy 
group or the non-chemotherapy group. This is the direct comparison that is of primary 
importance for reimbursement decisions. The MINDACT authors stated that the five-year DMFS 
(the primary study endpoint) was not significantly different. Because the study was not 
sufficiently powered to assess these differences, this finding should not be interpreted as 
evidence of absence of a therapeutic effect [76].  
 
Furthermore, since the PPS analysis of five-year DFS was significant (p=0.009), it is assumed 
that the investigated group was large enough to reveal an effect in DFS even without the 
power calculation targeting this secondary analysis. While the possibility of a chance finding 
always exists, since all outcome measures point in the same direction, it is doubtful that this 
effect arose by chance. Instead, we believe that this effect reveals a true difference between 
the two groups. This treatment effect may become more pronounced over the next five years 
because more events ((distant) recurrences and deaths) will occur.   
 
Based on the MINDACT it cannot be concluded that it is safe to omit chemotherapy, because 
the 95% CI’s of all surrogate outcomes (five-year DMFS, five-year DFS and five-year OS) for 
ten-year OS are crossing the non-inferiority threshold (HR 0.80 and 3% risk difference). 
However, the point estimates are on the left side of the non-inferiority threshold. It is 
therefore reasonable to assume that using MammaPrint® may result in an (clinically-relevant) 
increased risk of death in comparison with AO! risk assignment.  
 
The ESMO-MCBS criteria have been criticised [73-75]. ESMO uses the lower boundary of the 
95% CI to determine if a statistical significant difference is clinically relevant, so small trials 
qualify more easily for efficacy than large trials of identical efficacy, since small trials generally 
have wide 95% CIs. It has been suggested that the point estimate should be used instead 
[74,75]. However, even the point estimate of five-year DFS of 0.57 crosses the ESMO-MCBS 
threshold of 0.80 and even the HR 0.65 threshold, suggesting a substantial level of clinical 
benefit for DFS from chemotherapy following clinical risk assignment. Another critique is that, 
in the ESMO-MCBS, surrogates as primary endpoints have equal weight to the patient-relevant 
endpoints of OS and QoL. The effect can still be considered clinically relevant, but the ten-year 
survival data is mandatory to definitively confirm that the effect is clinically relevant. 
Furthermore, no rational arguments are provided for the threshold values [75]. Another 
criticism is that the credibility of the ESMO-MCBS would be augmented by external validation, 
for example comparing its results with those of HTAs carried out in Europe [73]. Cherney at al. 
[76,77] reported that this form of correlative validation has been carried out and shows a very 
high degree of concordance with the published evaluation of the same agents using the ESMO-
MCBS. They suggested that the methodology incorporated into the ESMO-MCBS is remarkably 
consistent with EUnetHTA guidelines for outcome measures, surrogate endpoints, health-
related QoL, and the application of these outcomes in relative effectiveness evaluations. An 
adapted version of the ESMO-MCBS criteria suggested by Wild et al. [75] is already used in 
HTA assessments.  
 
Despite the lack of consensus for using the ESMO-MCBS criteria, using no loss in OS as a non-
inferiority threshold or even other thresholds for non-inferiority (Table 3.2) will lead to the 
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same conclusion: the 95% CI’s of all surrogate outcomes cross these thresholds or it is 
reasonable to expect that these thresholds will be crossed in the next five years. The IQWiG 
also came to this conclusion [11]. Therefore, non-inferiority in terms of survival cannot be 
concluded. However, each HTA-organisation, needs to decide individually which non-inferiority 
threshold and clinical relevant thresholds are considered best for their assessment. 
 
 
7.2 PP or PPS analysis 
 
Due to the temporary change in risk as a result of assay problems, all risk groups as enrolled 
in that particular period are somewhat biased due to incorrect risk assessment. In addition to 
the prespecified PP analyses, so-called PPS analysis is also presented in the MINDACT 
publication, in which all patients enrolled during the period of change in risk were excluded. 
This PPS analysis is the least biased as the legend of table S5 of the MINDACT publication 
confirms. This PPS analysis is presented as sensitivity analysis, but in fact this PPS analysis 
represents the least biased and therefore most conservative PP analysis. Because the 
supplement of the MINDACT in which the PPS analysis was presented may not have undergone 
peer review, it could be argued that it should not be used as primary analysis in this 
assessment. But even if it is used in the way it is presented, i.e. as a sensitivity analysis, it is 
of complementary and confirmative information in order to assess the robustness of the 
findings and herewith an important way to assess the final impact of the study results for 
clinical practice. Unfortunately, the PPS analysis points in the direction in which the 
MammaPrint® group scores worse, thereby casting doubt on the robustness of the prespecified 
PP analysis. In addition, when the results of the PP analysis were used, instead of the PPS, the 
conclusion on clinical utility of the MammaPrint® would have been the same.  
 
7.3 Surrogate endpoints for ten-year OS 
 
In general there is no consensus on the use of surrogate endpoints to assess (added) clinical 
benefit of a health technology, because the relationship between a patient-relevant clinical 
endpoint and its various surrogates has rarely been investigated in such depth that one 
particular surrogate is universally accepted as a replacement [78]. Each country/HTA 
organisation, needs to decide individually which surrogate endpoint is considered best for their 
assessment. Therefore, the relevance of each endpoint is described, based on its biological 
plausibility and empirical evidence, providing specific information relevant for each endpoint. 
In summary: DMFS has a biological rationale and the MammaPrint® is developed as predictor 
for five-year DMFS, whereas DFS is also a relevant patient related outcome, as it includes all 
types of recurrences. Therefore, DFS reflects for the patient all stressful events, even when the 
disease is still curable, potentially impacting quality of life [59]. 
 
MINDACT’s primary endpoint is five-year DMFS in the CH/GL discordant risk group. According 
to the study authors, five-year DMFS is the primary endpoint as distant metastasis from breast 
cancer represents a virtually incurable disease with almost 100% mortality. The MINDACT 
authors stated that five-year DMFS was not significantly different and that the five-year results 
can be considered as mature data. However, as noted above, the DMFS results have a wide CI, 
as do the other endpoints. Expressed in absolute numbers, omitting chemotherapy after 
following MammaPrint® risk assessment and not AO! can lead to 100 (of 1000) more patients 
that will not be free of distant metastases after five years. Looking at the 95% CI of five-year 
DMFS, it could also lead to six less or at worst 287 more patients who are not free of distant 
metastases after five years (see Table A11 in Appendix 1). The 95% CI shows that there is a 
lot of uncertainty and a possibility that many patients could be harmed. Furthermore, there is 
an on-going risk of distant recurrence after five years. This is especially the case in ER-
positive/HER2-negative (luminal-type) breast cancer, where recurrences occur after five years 
in approximately one half of all distant recurrence cases [23]. Since ER-positive/HER2-negative 
tumours comprise the majority of the MINDACT study population, many distant metastasis 
cases might be expected. The benefit of adjuvant chemotherapy is primarily limited to 
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reducing recurrences within the first five years, however it is unclear whether these late 
recurrences are prevented by adjuvant chemotherapy [31-33]. Therefore, ten-year follow-up 
data is necessary. 
 
7.4 Quality of life/short- and long-term side effects of chemotherapy 
 
It is generally recognised that OS is the least ambiguous and most clinically relevant endpoint 
in clinical trials for cancer therapy. Beyond OS, the QoL endpoint is also very relevant. 
Unfortunately, QoL was not included in the MINDACT trial. According to the investigators, 
adding QoL questionnaires would be too burdensome for patients as they had to comprehend 
the complexities of the trial, including information on genomic testing. In addition, according to 
the investigators, no validated instrument was available at the time of study. Therefore, the 
TRANSBIG consortium, which involved patients and advocates, decided not to include a QoL 
evaluation in the overall study population.  
 
Although long-term QoL is not directly measured in the MINDACT trial, it may be argued that 
some aspects of QoL are reflected by other outcomes. As mentioned in Section 4.2.6 it is 
known that the QoL of patients receiving adjuvant chemotherapy will be reduced due to 
chemotherapy side effects during and shortly after treatment compared to patients who do not 
receive chemotherapy. In addition, the MINDACT study shows that refraining from 
chemotherapy leads to a significant and clinically-relevant worse five-year DFS. Nearly all 
types of recurrences are stressful to patients even in the case of a curable disease. This 
distress will have its repercussions on quality of life. Retel et al. [13] conclude in their QoL 
assessment 6-8 weeks after their decision regarding adjuvant chemotherapy that patients 
were generally satisfied with the information they received about recurrence risk based on the 
MammaPrint®, but clinicians should be aware that genomic test results may be associated with 
greater distress levels, especially for patients with high recurrence risk or discordant test 
results. Because long-term QoL is not available in the MINDACT, the added value of the 
MammaPrint® in terms of QoL in the long term cannot be quantified. 
 
Toxicity data is measured in the MINDACT trial but are not yet published. When considering 
the protocol, future analyses will be limited to a comparison between side effects of the two 
regimens of chemotherapies and endocrine therapy. At this time, it is only known from 
previous publications that chemotherapy has an absolute risk of heart failure or leukaemia of 
approximately 2% [79,80]. The absence of data on toxicity will not be critical when data on OS 
and QoL would be available, as toxicity will have its repercussions on QoL and/or OS.  
 
7.5  Clinical utility of MammaPrint® 
 
Each HTA-organisation will need to decide individually which non-inferiority threshold and 
clinical relevant thresholds are considered most appropriate for their assessment considering 
the local context. Based on the chosen thresholds in this EUnetHTA assessment report, 
conclusions are as follows: 
 
Taking everything into consideration, it has not yet been demonstrated that patient outcomes 
(ten-year OS and QoL) are improved by withholding adjuvant chemotherapy based on 
MammaPrint® testing in the CH/GL risk group (Table 7.1). In other words, the clinical utility of 
the MammaPrint® is not proven. This conclusion is based on the absence of evidence on added 
value in terms QoL and on the fact that non-inferiority in terms of OS (surrogates five-year 
DMFS, five-year DFS and five-year OS) is not shown. Next to that there are concerns about 
the certainty of five-year DMFS because of the imprecision (very wide 95% CI’s). Therefore 
the results do not rule out the possibility of a clinically-relevant increase in distant metastasis 
and hence risk of death. Also, the significant and clinically-relevant difference in DFS is of 
importance as QoL data is not available. The quality of the evidence for the critical ten-year OS 
endpoint was rated as low to very low. Therefore, the confidence in the OS effect estimate 
after ten years is limited at best. 
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Furthermore, a clinical benefit of receiving chemotherapy in the CL/GH risk group according to 
genomic risk assignment has not been demonstrated. The quality of the evidence for the 
critical ten-year OS endpoint was rated very low. Therefore, there is very little confidence in 
the effect estimate, and the true effect is likely to be substantially different from the effect 
estimate.  
 
Ten years of follow-up will be needed to conclude if an add-on risk assessment approach (AO! 
combined with MammaPrint®) has superior clinical utility compared with treatment decisions 
based on AO! alone. At that time, the level of evidence of the data and therefore confidence in 
the data will be higher, because the use of surrogate endpoints will no longer be necessary. If 
a revision of AO! becomes available, as is expected, this could have an impact on the baseline 
risks of recurrence and hence may potentially limit the clinical applicability of the MINDACT 
results. 
 
Ultimately, the decision to receive or forgo chemotherapy (or any other treatment) lies with 
each patient who is properly informed about the potential side effects and the potential 
benefits of such treatment. For the same risk–benefit scenario, different patients may make 
different decisions. However, well-informed decision making is only possible if both parameters 
(OS and QoL) had been quantified. 
 
Table 7.1 Clinical utility of MammaPrint® in the different risk groups 
Risk group Add-on test (MammaPrint®) 
results in MINDACT 
Clinical utility (five-year 
follow-up) 
CH/GL Following MammaPrint® potentially 
leads to significant and clinically 
relevant decreased survival (five-year 
DFS absolute difference of 4.5% 
HR=0.57 (95% CI 0.37-0.87; 
p=0.009) 
 
Not proven, results indicate 
potentially inferiority of 
treatment decision based on 
MammaPrint® 
  
CH/GH Concordant risk group, treatment 
decision is chemotherapy 
 
Clinical utility not relevant  
CL/GH Clinical benefit of genomic risk 
assignment not demonstrated but a 
clinical benefit of MammaPrint® based 
treatment decision cannot be ruled out 
 
Not proven  
CL/GL Concordant risk group, treatment 
decision is no chemotherapy 
Clinical utility not relevant 
Abbreviations: CH: clinical high; CL: clinical low; DFS: disease-free survival; GH: genomic high; GL: 
genomic low; HR: hazard ratio. 
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9 APPENDIX 1 
 
9.1 History/background  
 
Table A 1. Descriptive summary of the scoping search results1 
Authors (year) Sponsor/count
ry 
Search period and 
outcome measures 
Evaluated tests Conclusions 
Marchionni 
(2008) [6] 
AHRQ/USA 1990-2006 
Clinical effectiveness: 
analytical and clinical 
validity 
Oncotype DX®, 
MammaPrint®, and 
H/I. 
The body of evidence shows that the tests offer clinically relevant, 
improved risk stratification over standard predictors. Oncotype DX® 
has the strongest evidence, closely followed by MammaPrint® and 
H/I (which is still maturing). 
Smartt (2009) 
[7]  
HSAC/NZ 2007-2009 
Effectiveness  
 
Oncotype DX®, 
MammaPrint® 
HOXB13:IL17BR 
This update did not identify any studies providing direct, high-quality 
evidence that the investigated gene expression profiling tests lead to 
improvement in outcomes or are able to predict response to 
chemotherapy in any sub-set of women diagnosed with breast 
cancer. 
OHTA (2010) 
[81]  
 
OHTA/CA 2006-2010  
Laboratory performance, 
prognostic and predictive 
value and cost-
effectiveness 
Oncotype DX® There is currently insufficient evidence investigating how Oncotype 
DX® would impact clinician/patient decision-making in a setting 
generalizable to Ontario. 
Ward (2011) [8]  NICE/UK 2009-2011 (for Oncotype 
DX®) and 2002-2011 (for 
MammaPrint®):  
Clinical effectiveness 
(analytic and clinical 
validity, clinical utility) and 
cost-effectiveness for nine 
tests 
 
BluePrint®, Breast 
Cancer Index (BCI), 
IHC4, MammaPrint®, 
Mammostrat, NPI 
plus (NPI+), 
Oncotype DX®, 
PAM50 and Randox 
Breast Cancer Array. 
The clinical evidence base for Oncotype DX® is considered to be the 
most robust. For MammaPrint® and Mammostrat there were 
significant gaps in the available evidence. Evidence for the remaining 
five tests (PAM50, NPI+, BCI, BluePrint® and Randox®) was limited. 
San Miguel 
(2015) [5] 
KCE/Belgium 2011-2014 
Clinical validity and cost-
Oncotype DX®, 
PAM50, MapQuant 
The evidence for Oncotype DX® is more robust than the evidence for 
other tests. Important evidence gaps are still present. It is not yet 
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effectiveness  
 
 
DX®, H/I (replaced 
by BCI),  
EndoPredict®,  
Mammaprint®, 
BluePrint®, Randox 
Breast Cancer Array, 
Mammostrat®, NPI+, 
IHC4, uPA/PAI-1 
clear to what extent the use of the MammaPrint® test will change 
the management of patients and to what extent chemotherapy 
would be offered to patients classified as having a good or a poor 
prognosis with MammaPrint®. 
Marrone (2015) 
[10]  
Academic/USA 2007-2013 
Clinical utility  
Oncotype DX® and 
MammaPrint®, 
Indirect evidence showed Oncotype DX® was able to predict 
treatment effects of adjuvant chemotherapy, whereas no evidence of 
predictive value was found for MammaPrint®. Both tests influenced a 
change in treatment recommendations in 21 to 74% of participants.  
 IQWiG (2016) 
[11]  
IQWiG/Germany ?-2016 
Clinical validity and clinical 
utility 
Oncotype  
DX®, PAM50 risk-of-
recurrence 
score/Prosigna® 
Breast Cancer 
Prognostic Gene 
Signature Assay, 
Breast Cancer Index, 
IHC4 
There is currently no hint of a benefit or harm of a biomarker-based 
strategy to support the decision for or against adjuvant 
chemotherapy.  
 
1 Clinical trial databases were searched to identify studies evaluating the clinical effectiveness of GES tests: MammaPrint®, Oncotype DX®, PAM50, MapQuant 
DX, H/I*, EndoPredict®, BluePrint®, Randox Breast Cancer Array, Prosigna®, and the Breast Cancer Index. 
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9.2 Documentation of the search strategies  
  
Search terms were:  
Medline (PubMed): "Gene Expression Profiling"[Mesh] AND (mammaprint[tiab] OR 70 
gene[tiab] OR MINDACT[tiab]) AND "Breast Neoplasms"[Mesh] 
Limit: from June 2014, English, Dutch 
22 references 
 
Not yet indexed publications 
((mammaprint[tiab] OR 70 gene[tiab] OR MINDACT[tiab]) AND breast*[tiab]) NOT Medline[sb] 
Limit: from June 2014, English, Dutch 
25 references 
 
Embase 
mammaprint:ab,ti OR '70 gene':ab,ti AND 'breast tumor'/exp AND [embase]/lim NOT 
[medline]/lim  
Limit: from 2015, English, Dutch 
6 references (after removing duplicates) 
 
 
Table A 2. Baseline Characteristics, According to Risk Group.a  
Characteristics Low clinical risk High clinical risk All 
Patients 
(n=6693) 
  Low 
genomic 
risk 
(n=2745) 
High 
genomic 
risk 
(n=592) 
Low 
genomic 
risk 
(n=1550) 
High 
genomic 
risk 
(n=1806) 
 
  Number (%) 
Age, yr      
 <35 24 (0.9) 13 (2.2) 20 (1.3)  65 (3.6) 122 (1.8) 
 35 to <50 774 (28.2) 165 (27.9) 514 (33.2) 651 (36.0) 2104 
(31.4) 
 50 to 70 1928 (70.2) 403 (68.1) 1000 
(64.5) 
1080 
(59.8) 
4411 
(65.9) 
 >70 19 (0.7) 11 (1.9) 16 (1.0) 10 (0.6) 56 (0.8) 
Tumour size, cmb      
 <1 655 (23.9) 198 (33.4) 38 (2.5) 29 (1.6) 920 (13.7) 
 1 to 2 1968 (71.7) 383 (64.7) 610 (39.4) 914 (50.6)  3875 
(57.9) 
 >2 to 5 122 (4.4) 11 (1.9) 843 (54.4) 843 (46.7) 1819 
(27.2) 
 >5 0 0 58 (3.7) 20 (1.1) 78 (1.2) 
Tumour gradec      
 1 1242 (45.2) 92 (15.5) 98 (6.3) 15 (0.8) 1447 
(21.6) 
 2 1457 (53.1) 414 (69.9) 995 (64.2) 421 (23.3) 3287 
(49.1) 
 3 36 (1.3) 83 (14.0) 443 (28.6) 1365 
(75.6) 
1927 
(28.8) 
 Missing data 10 (0.4) 3 (0.5) 14 (0.9) 5 (0.3) 32 (0.5) 
Lymph node statusd      
9.3 Description of the evidence used 
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Characteristics Low clinical risk High clinical risk All 
Patients 
(n=6693) 
  Low 
genomic 
risk 
(n=2745) 
High 
genomic 
risk 
(n=592) 
Low 
genomic 
risk 
(n=1550) 
High 
genomic 
risk 
(n=1806) 
 
 Negative 2570 (93.6) 577 (97.5) 812 (52.4) 1329 
(73.6) 
5288 
(79.0) 
 Positive      
 1 node 131 (4.8) 10 (1.7) 505 (32.6) 296 (16.4) 942 (14.1) 
 2 nodes 26 (0.9) 3 (0.5) 157 (10.1) 114 (6.3) 300 (4.5) 
 3 nodes 18 (0.7) 2 (0.3) 69 (4.5) 65 (3.6) 154 (2.3) 
 ≥4 nodes 0 0 6 (0.4) 2 (0.1) 8 (0.1) 
Hormone receptor statuse      
 ER-positive, PR positive, or 
both 
2741 (99.9) 535 (90.4) 1520 
(98.1) 
1118 
(61.9) 
5914 
(88.4) 
 ER-negative and PR-
negative 
4 (0.1) 57 (9.6) 29 (1.9) 688 (38.1) 778 (11.6) 
HER2 statusf      
 Negative 2641 (96.2) 518 (87.5) 1423 
(91.8) 
1461 
(80.9) 
6043 
(90.3) 
 Positive 97 (3.5) 73 (12.3) 124 (8.0) 344 (19.0) 638 (9.5) 
 Missing data 7 (0.3) 1 (0.2) 3 (0.2) 1 (0.1) 12 (0.2) 
       
Clinicopathological subtypeg      
 Luminal HER2-negative: ER-
positive, PR-positive, or both 
2638 (96.1) 467 (78.9) 1402 
(90.5) 
895 (49.6) 5402 
(80.7) 
 Luminal HER2-positive: ER-
positive, PR-positive, or both 
96 (3.5) 68 (11.5) 115 (7.4) 222 (12.3) 501 (7.5) 
 Non-luminal HER2-positive: 
ER-negative, PR negative 
1 (<0.1) 5 (0.8) 9 (0.6) 122 (6.8) 137 (2.0) 
 Triple negative: ER-
negative, PR-negative, 
HER2-negative 
3 (0.1) 51 (8.6) 20 (1.3) 566 (31.3) 640 (9.6) 
 Missing data 7 (0.3) 1 (0.2) 4 (0.3) 1 (0.1) 13 (0.2) 
WHO performance statush      
 0 2644 (96.3) 565 (95.4) 1491 
(96.2) 
1734 
(96.0) 
6434 
(96.1) 
 1 101 (3.7) 27 (4.6) 58 (3.7) 71 (3.9) 257 (3.8) 
 2 0 0 1 (0.1) 1 (0.1) 2 (<0.1) 
       
Abbreviations: ER: oestrogen receptor; ; PR: progesteron receptor HER2: human epidermal growth 
factor 2 receptor;  
 
a Data was missing for one patient at high clinical and low genomic risk with respect to tumour size, lymph 
node status, and hormone receptor status. Percentages may not total 100% because of rounding. ER 
denotes oestrogen receptor, HER2 human epidermal growth factor receptor, and PR progesterone 
receptor.  
b A majority of patients at high clinical and low genomic risk (54%) had tumours measuring 2 to 5 cm in 
diameter. Most of the patients at low clinical and genomic risk (96%) and at low clinical and high genomic 
risk (98%) had tumours measuring 2 cm or less, as did 52% of the patients at high clinical and genomic 
risk.  
c More than three quarters (76%) of patients at high clinical and genomic risk had grade 3 tumours. Most 
patients at low clinical and genomic risk, low clinical and high genomic risk, and high clinical and low 
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genomic risk had grade 1 or 2 tumours (98%, 85%, and 71%, respectively).  
d The presence of negative lymph nodes was substantially more frequent among patients at low clinical 
and genomic risk (94%) and low clinical and high genomic risk (97%) than among patients at high clinical 
and low genomic risk (52%) and high clinical and genomic risk (74%).  
e Almost all tumours were positive for hormone receptors except among patients at high clinical and 
genomic risk, in whom 38% of tumours were hormone receptor-negative. Hormone receptor positivity was 
defined as the presence of at least 1% immunoreactive cells, an Allred score of greater than 2 (on a scale 
from 0 to 8, with higher scores indicating a greater number of receptors), or a level of cytosolic protein of 
at least 10 fmol per milligram.  
f HER2 positivity was reported in 4% of patients at low clinical and genomic risk, 12% of those at low 
clinical and high genomic risk, 8% of those at high clinical and low genomic risk, and 19% of those at high 
clinical and genomic risk.  
g Specifically, among patients at high clinical and low genomic risk, 48% had node-positive disease, 58% 
of tumours measured 2 cm or more, and 90% had the luminal HER2-negative subtype.  
h The World Health Organization performance scores range from 0 to 5, with 0 denoting perfect health and 
5 death. 
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Table A 3. Overview of ‘surrogate’ intrinsic breast cancer subtypes [45] 
Intrinsic subtype Prognosis 
Luminal A (50-60%) 
‘Luminal A-like’ 
 ER-positive, HER2-negative, Ki67 low*, PR 
high** 
Low-risk molecular signature (if available) 
 
Good 
Recurrence common in bone 
 
Luminal B (15-20%) 
‘Luminal B-like (HER2-negative)’ 
 ER-positive, HER2-negative, and either Ki67 
high or 
 PR low 
High-risk molecular signature (if available) 
 
Poor 
Increased relapse rate in the first five 
years after diagnosis [82] 
 
‘Luminal B-like (HER2-positive)’ 
 ER-positive, HER2-positive, any Ki67, any PR 
 
 
HER2 overexpression (15-20%) 
‘HER2-positive (non-luminal)’ 
   HER2-positive, ER and PR absent 
   
Poor 
‘Basal-like’ (8-37%)*** 
‘Triple-negative (ductal)’ 
 ER and PR absent 
 HER2-negative 
 
Poor 
Metastasis to brain and lung 
Abbreviations: ER: oestrogen receptor; PR: progesteron receptor HER2: human epidermal growth factor 
2 receptor;  
* Ki67 scores should be interpreted in the light of local laboratory values: as an example, if a laboratory 
has a median Ki67 score in receptor-positive disease of 20%, values of 30% or above could be considered 
clearly high; those of 10% or less clearly low.  
** Suggested cut-off value is 20%; quality assurance programmes are essential for laboratories reporting 
these results.
  
*** There is ∼80% overlap between ‘triple-negative’ and intrinsic ‘basal-like’ subtype, but ‘triple-negative’ 
also includes some special histological types such as (typical) medullary and adenoid cystic carcinoma with 
low risks of distant recurrence [45]. 
  
9.3.1 Guidelines for diagnosis and management  
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Figure A 1. Treatment algorithm according to the ESMO guideline for breast  
cancer treatment [40]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ER: oestrogen receptor; HER2: human epidermal growth factor 2 receptor; ChT: 
chemotherapy; ET: endocrine therapy; T: trastuzumab.
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Table A 4. Overview of guidelines 
 
Name of 
society/organisation 
issuing guidance 
 
Date of 
issue 
 
 
Country  
 
Summary of recommendation 
 
Clinical practice guidelines published after the MINDACT publication 
 
St Gallen[45] 
 
 
2017  
 
International In ER-positive, HER2-negative, lymph node-negative breast cancer, MammaPrint® is endorsed as a 
prognostic marker for adjuvant endocrine therapy in node-negative breast cancers. It is also 
recommended for guiding the decision on adjuvant chemotherapy in node-negative tumours, 
identifying cases at low risk, with an excellent prognosis that would not warrant chemotherapy. 
 
In ER-positive, HER2-negative, lymph node-positive breast cancer, gene expression signatures were 
not uniformly endorsed for making treatment decisions regarding adjuvant chemotherapy in node-
positive cases. Only MammaPrint® and Oncotype DX® were recommended. Patients with low-risk 
tumour scores and a limited degree of nodal involvement appear to have a good prognosis with or 
without chemotherapy. 
American Joint 
Committee on Cancer 
(AJCC)[40] 
 
2017 USA/ 
International 
the AJCC Task Panel recognizes that MammaPrint® has Level 1 evidence, based on MINDACT, for 
determining clinical prognosis. MammaPrint® is currently the only breast cancer risk of recurrence 
test that is recognized by ASCO and AJCC for use in clinically high risk patients. 
Additionally, they do not endorse the use of any specific multigene genomic panel. These statements 
clarify that the use of MammaPrint® is compliant with Commission on Cancer – National Accreditation 
Program for Breast Centers (CoC-NAPBC) accreditation standards. 
American Society of 
Clinical Oncology (ASCO) 
[41]  
 
2017  USA If a patient has ER/PR–positive, HER2-negative, node-negative breast cancer, the MammaPrint® 
(Agendia, Irvine, CA) assay may be used in those with high clinical risk per MINDACT categorisation 
to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a 
good-prognosis population with potentially limited chemotherapy benefit. 
 
If a patient has ER/PR–positive, HER2-negative, node-negative breast cancer, the MammaPrint® 
assay should not be used in those with low clinical risk per MINDACT categorisation to inform 
decisions on withholding adjuvant systemic chemotherapy, because women in the low clinical risk 
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category had excellent outcomes and did not appear to benefit from chemotherapy even with a 
genomic high-risk cancer. 
 
If a patient has ER/PR–positive, HER2-negative, node positive breast cancer, the MammaPrint® assay 
may be used in patients with one to three positive nodes and at high clinical risk per MINDACT 
categorisation to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to 
identify a good prognosis population with potentially limited chemotherapy benefit. However, such 
patients should be informed that a benefit of chemotherapy cannot be excluded, particularly in 
patients with greater than one involved lymph node. 
 
If a patient has ER/PR–positive, HER2-negative, node-positive breast cancer, the MammaPrint® assay 
should not be used in patients with one to three positive nodes and at low clinical risk per MINDACT 
categorisation to inform decisions on withholding adjuvant systemic chemotherapy. There are 
insufficient data on the clinical utility of MammaPrint® in this specific patient population. 
 
If a patient has HER2-positive breast cancer, the clinician should not use the MammaPrint® assay to 
guide decisions on adjuvant systemic therapy. Additional studies are required to address the role of 
MammaPrint® in patients with this tumour subtype who are also receiving HER2-targeted therapy. 
 
If a patient has ER/PR negative and HER2-negative (triple negative) breast cancer, the clinician 
should not use the MammaPrint® assay to guide decisions on adjuvant systemic chemotherapy. 
 
National Comprehensive 
Cancer Network[83]  
2017 USA The 70-gene signature assay is approved by the FDA to assist in assignment of women with ER-
positive or ER-negative breast cancer into a high versus a low risk of recurrence, but not for 
predicting benefit from adjuvant systemic therapy. The prospective RASTER study reported that 
breast cancer patients classified by the 70-gene signature as low risk (of whom 85% did not receive 
adjuvant chemotherapy) had an overall 97% distant recurrence free interval at five years. The NCCN 
panel members acknowledge that many assays have been clinically validated for prediction of 
prognosis.  
 
The MINDACT trial is a phase III trial comparing the 70-gene signature with the commonly used 
clinicopathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 
3 nodes. The early results from the MINDACT trial suggest that the 70-gene signature can help avoid 
    MammaPrint® for early breast cancer 
 
 
 
    
 
Version 1.3, December 2017                           EUnetHTA JA3 WP4                              72                                                                                
  
chemotherapy in certain patients regardless of larger tumour size and nodal status, without 
compromising the outcome.  
 
AETSA[84] 2017 Spain Mammaprint® to assess necessity of adjuvant chemotherapy in females or males with recently 
diagnosed breast tumors, where all of the following criteria are met: 
A. Breast cancer is nonmetastatic (node negative1) or with 1-3 involved ipsilateral axillary lymph 
nodes; and 
B. Breast tumor is estrogen receptor positive or progesterone receptor positive; and 
C. Breast tumor is HER2 receptor negative (Rationale: adjuvant chemotherapy with trastuzumab 
(Herceptin) is considered to be medically necessary regardless of Mammaprint® score for HER2 
receptor positive lesions); and 
D. Member is determined to be at "high clinical risk" of recurrence using Adjuvant! Online ( (see page 
20 of MINDACT study supplement for definitions of high clinical risk; and 
E. Adjuvant chemotherapy is not precluded due to any other factor (e.g., advanced age and/or 
significant co-morbidities); and 
F. Member and physician (prior to testing) have discussed the potential results of the test and agree 
to use the results to guide therapy. 
 
AGO (German 
Gynecological Oncology 
Group)  
2017 Germany 2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint® test with 
highest medical evidence level 1A for identification of patient subgroups who can potentially forgo 
chemotherapy for breast cancer 
 
Guidelines before the MINDACT publication. 
 
Cancer Care Ontario[85] 2016 Canada Recommendations  
• Clinicians may offer multigene profile assay testing to potential chemotherapy candidates with 
invasive breast carcinoma that is ER-positive/HER2-negative.  
• In patients with node-negative ER-positive/HER2-negative disease, clinicians may use a low-risk 
result from Oncotype DX®, Prosigna, or EndoPredict/EPclin assays to support a decision to 
withhold chemotherapy.  
• In patients with node-negative ER-positive/HER2-negative disease, clinicians may use a high-
risk result from Oncotype DX® to support a decision to offer chemotherapy. A high-risk 
Oncotype DX® result in this subpopulation has been associated with both poor prognosis 
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without chemotherapy, and a prediction of benefit from giving chemotherapy. 
• In some patients with ER-positive/HER2-negative tumours and 1-3 nodes involved (N1a 
disease), clinicians may withhold chemotherapy based on a low-risk Oncotype DX® or 
Prosigna score if the decision is supported by other clinical, pathological, or patient-related 
factors.  
• In patients with ER-positive disease, there is insufficient evidence to recommend the use of 
multigene profiling assays to inform clinical decision making for late risk of recurrence. A 
high-risk score using Prosigna or EndoPredict prognosticates for late recurrence; however, 
evidence is lacking that these tests predict for benefit of extended adjuvant endocrine 
treatment beyond five years.  
 
Mammaprint® 
Three identified studies assessed the prognostic ability of MammaPrint®. Based on the tumour marker 
utility grading system, all three studies were assessed as category C studies. The three studies 
reported consistent findings; however, since the studies were assessed as category C studies, the 
overall evidence supporting the prognostic ability of MammaPrint® is considered to be level II.  
 
The original prospective observational study by van de Vijver et al. classified patients into poor or 
good prognosis based on MammaPrint® findings and found that scores were prognostic of early 
distant recurrence. The other two prospective observational studies analysed RNA extracted from the 
tumour samples of patients enrolled in the microarRAy prognoSTics in breast cancer (RASTER) study. 
The first publication compared the risk of five-year distant-recurrence free interval predicted by 
MammaPrint® with the predicted risk determined by Adjuvant! Online and found that MammaPrint® 
added prognostic value above the clinicopathological risk estimate of Adjuvant! Online. The second 
publication found that MammaPrint® score was able to prognosticate early distant recurrence 
independent of a clinical risk estimate. MammaPrint® has Level II evidence supporting its use as a 
prognostic tool for distant recurrence due to the category C studies assessing this clinical utility.  
European Society for 
Medical Oncology 
ESMO[42] 
2015 Europe Gene expression profiles, such as MammaPrint® (Agendia, Amsterdam, the Netherlands), Oncotype 
DX® Recurrence Score (Genomic Health, Redwood City, CA), Prosigna (Nanostring technologies, 
Seattle, WA) and Endopredict (Myriad Genetics), may be used to gain additional prognostic and/or 
predictive information to complement pathology assessment and to predict the benefit of adjuvant 
chemotherapy. The three latter tests are designed for patients with ER-positive early breast cancer 
only. 
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The clinical utility of MammaPrint® and Oncotype DX® is still being prospectively evaluated in large 
randomised clinical trials such as MINDACT for MammaPrint®, WSG PLAN B trial, TAILORx and 
RxPONDER for Oncotype DX®. A IB evidence level has been achieved from retrospective analyses of 
data from prospective trials regarding the prognostic value of MammaPrint®, Oncotype DX®, 
Prosigna, and Endopredict in ER-positive breast cancers. In addition, the prognostic value of 
MammaPrint® has been validated in the Raster trial, a prospective but nonrandomised, clinical trial. 
KCE[5]  2015 Belgium Revision of this guideline is currently in progress. 
 
The current guideline recommends (adapted from Ward et al. [9]) 
The present overview of systematic reviews on the effectiveness of gene expression profiling and 
expanded immunohistochemistry tests for early breast cancer shows that most evidence is available 
for Oncotype DX® (RT-PCR) and MammaPrint® (microarray GEP). In general, the evidence is mainly 
limited to their clinical validity (i.e., prognostic ability), and no RCTs appear to be available yet. For 
several tests (e.g. Oncotype DX®, MammaPrint®, Mammostrat), the evidence supporting their 
prognostic ability is quite strong, but this only gives indirect information about the clinical utility of 
these tests. Direct evidence (e.g., test-and-treat RCTs, comparative observational studies) evaluating 
the effect of management strategies incorporating these tests on clinical outcomes (i.e., survival, 
recurrence, etc.) is generally lacking. Would the GRADE system have been used in this report to 
assign a level of evidence to the conclusions, the indirectness of the evidence concerning patient-
important outcomes such as survival would have immediately led to a downgrading to low or very low 
level evidence, even though the level of prognostic evidence is high in itself.  
AHRQ[86] 2014 Maryland, 
USA 
Conclusions 
We found no evidence to determine whether using the tests to estimate prognosis leads to improved 
outcomes for patients. 
 
MammaPrint®  
Our meta-analysis suggests that patients classified as having a poor prognosis by MammaPrint® 
consistently do worse than those with a good prognosis signature with respect to distant metastatic-
free survival and CSS. Studies included in the search varied somewhat in the subpopulations they 
tested; the fact that the signature added prognostic value across these various subpopulations 
suggests that it has broad applicability. Because no studies looked at the value of MammaPrint® with 
respect to loco-regional recurrence (LRR) and only one considered overall survival, there is scant or 
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no evidence regarding the clinical validity of the MammaPrint® signature in terms of these outcomes. 
Institut National du 
Cancer (INCa)[87]  
2013 France 
 
In 2013, The French National institute of Cancer (InCa) concluded there was not enough evidence of 
added value with MP compared to usual clinico-pathological prognostic factors. Without this prove of 
added value, clinical utility of a novel marker as MP couldn’t be established at time of the French 
report. The National institute of Cancer concludes there is not enough evidence for recommendations. 
 
 
NICE[88]  2013 UK Revision of this guideline is currently in progress. 
 
The current guideline recommends:  
MammaPrint®, IHC4 and Mammostrat are only recommended for use in research in people with ER+, 
LN- and HER2- early breast cancer to collect evidence about potentially important clinical outcomes 
and to determine the ability of the tests to predict the benefit of chemotherapy. The tests are not 
recommended for general use in these people because of uncertainty about their overall clinical 
benefit.  
DKG[89]  2012 Germany Revision of this guideline is currently in progress  
 
Recommendations according to the guideline from 2012: 
The EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group comes to 
the conclusion that because of inadequate evidence, no recommendation regarding the use of gene 
expression profiles can be given (see 
http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/GEP_provider.htm). Since the studies 
published in the meantime do not abolish these general deficits, it is currently not possible to make a 
recommendation for everyday practice therapy decisions regarding gene expression-analysis. 
Nationale BorstKanker 
Overleg Nederland 
(NABON)[90]  
2012 Netherlands Revision of this guideline is currently in progress  
 
The current NABON guidelines recommend that MammaPrint® may be used in individual cases with a 
hormone sensitive invasive ductal carcinoma if there is doubt about the indication for adjuvant 
chemotherapy on the basis of traditional prognostic factors 
• In 2016, NABON issued an update letter in response to the impact of the publication of the 
MINDACT trial. It provisionally concluded that MammaPrint® may have added value in 
patients with pT1-2N0 and pT1-N1, ER-positive and HER2-negative invasive ductal breast 
cancer who are considered for chemotherapy 
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Unidad de Evaluacion de 
Tecnologias Sanitarias 
(UETS)[91]  
 
2012 Spain The document contains an economic evaluation of Oncotype DX®. This model does not provide 
information on the comparison with other tests such as MammaPrint®. There are more studies 
needed in this context between different commercialised tests, with more patients included, since the 
obtained results are not conclusive. 
 
Abbreviations: ER: oestrogen receptor; PR: progesteron receptor; HER2: human epidermal growth factor 2 receptor; GRADE: Grading of Recommendations, Assessment, 
Development and Evaluation; RCT: Randomised Controlled Trial. 
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Table A 5. Characteristics of randomised controlled study 
Author and 
year or 
study name 
Study type  Number of patients Intervention(s) Main endpoints Conclusion Authors Included in 
clinical 
effectiveness 
and/or safety 
domain 
Cardoso et al. 
2016 
MINDACT 
EORTC[4] 
RCT, open-label, 
randomisations 
centrally, PP and 
ITT analysis 
reported, 
multicentre (112) 
in 9 European 
countries. Follow-
up: primary 
endpoint five-
year DMFS. In 
addition ten-
years data will be 
collected. 10 
years and in case 
of endocrine 
therapy 15 years. 
Sponsoring see 
Table 3.1 
6693 
19-70 years 
Female 
Histologically confirmed 
primary breast cancer (stage 
T1, T2, or operable T3) lymph 
node-negative or up to three 
positive axillary nodes.  
In the high clinical risk group 
and the low genomic risk 
group (PPS analysis), 503 
patients received 
chemotherapy based on 
clinical risk and 542 patients 
did not receive chemotherapy 
based on genomic risk.  
MammaPrint® added to 
Adjuvant! Online for 
making decision 
chemotherapy yes or 
no compared with 
decision based only on 
Adjuvant! Online.  
Chemotherapy 
randomised: 
anthracycline or 
docetaxel-plus-
capecitabine regimen. 
Hormone+ randomized 
tamoxifen-letrozole or 
letrozole-only regimen. 
 
 
Primary: five-year 
distant metastasis-
free survival$ 
Secondary: 
Proportion of patients 
that received 
chemotherapy 
according to the 
clinical risk as 
compared with the 
genomic risk 
Overall survival* 
Disease-free 
survival# 
 
 
Among women with early-stage 
breast cancer who were at high 
clinical risk and low genomic risk 
for recurrence, the receipt of no 
chemotherapy on the basis of the 
70-gene signature led to a five-
year rate of survival without 
distant metastasis that was 1.5 
percentage points lower than the 
rate with chemotherapy. Given 
these findings, approximately 
46% of women with breast 
cancer who are at high clinical 
risk might not require 
chemotherapy.  
Eff /Saf 
Abbreviations:               
$: Survival without distant metastasis was defined as the time until the first distant metastatic recurrence or death from any cause. 
#: Disease-free survival was defined as the time until first disease progression (locoregional, distant relapse, ipsilateral or contralateral invasive breast cancer, ductal carcinoma 
in situ or an invasive second primary cancer or death from any cause.  
* Overall survival was defined as the time until death from any cause.  
9.3.1.1 Evidence tables of individual studies included for clinical effectiveness and safety 
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Table A 6: Reason for exclusion studies 
 
 Citation  Reason for exclusion 
1 Duffy et al, 2017 [92] Guideline- publication/consensus meeting  
2 Makama et al, 2017[93] Association study  
3 Whitworth et al, 2017[94] neo-adjuvant setting  
4 Xu et al. 2017[95] Concordance study with other prognostic tests 
(Miscellaneous) 
5 Poh, 2016[96] Comment/letter 
6 Araki et al. 2016[97] Other language 
 
7 Baron et al. 2016[98] neo-adjuvant setting 
 
8 Bartlett et al. 2016[99] Concordance study with other prognostic tests 
 
9 Beitsch et al. 2016[100] neo-adjuvant setting 
 
10 Beumer et al. 2016[101] Technical and/or clinical validation  
11 Beumer et al. 2016[102] Technical and/or clinical validation in invasive lobular 
carcinoma (duplicate with 55) 
12 Blok et al. 2016[103] Comment/letter 
13 Falato et al. 2016[104] Clinical validation  
14 Gregoire et al. 2016[105] Pre-clinical study 
15 Gyanchandani et al. 2016[106] Pre-clinical study 
16 Kuijer et al. 2016 [107] Decision impact study no outcomes on clinical utility  
17 Kuijer et al. 2016 [108] Decision impact study no outcomes on clinical utility  
18 Li et al. 2016[109] Miscellaneous 
19 Lopez et al. 2016[110] Miscellaneous 
20 Ma et al. 2016[111] Review  
21 Markopoulos et al. 2016[112] Review  
22 Myers et al. 2016[113] Review  
23 Nagarajan et al. 2016[114] Miscellaneous 
24 Nunes et al. 2016[115] Technical and/or clinical validation 
25 Patil et al. 2016[116] Miscellaneous 
26 Pohl et al. 2016 [117] Decision impact study no outcomes on clinical utility  
27 Ribnikar et al. 2016[118] Review  
28 Schilsky et al. 2016[119] Miscellaneous 
29 Schmidt C et al. 2016[120] Comment/letter 
30 Schmidt M et al. 2016[121] Review  
31 Stein et al. 2016[122] Technical and/or clinical validation 
32 Thewes et al. 2016[71] Comment/letter 
33 Van ’t Veer et al. 2016[123] Comment/letter 
34 Viale et al. 2016 [124] Technical and/or clinical validation  
35 Yerlikaya et al. 2016[125] Concordance study with other prognostic tests 
36 Gyorffy et al. 2015[126] Review  
37 Hadi et al. 2015[127] Review  
38 Marrone et al. 2015[10] Review 
39 Rahilly-Tierney et al. 2015[128] Related to costeffectiveness 
40 Segui et al. 2015[129] Comment/letter/review 
41 Shimizu et al. 2015[130] Technical and/or clinical validation 
42 Suo et al. 2015[131] concordance study 
43 Zemmour et al. 2015[132] Technical and/or clinical validation 
44 Bayraktar et al. 2014[133] neo-adjuvant setting 
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45  Bonastre et al. 2014[134] Related to cost-effectiveness 
46 Cusumano et al. 2014[135] Decision impact study no outcomes on clinical utility  
 
47 Drukker et al. 2014 [136] Technical and/or clinical validation 
48 Drukker et al. 2013 [12] No supportive evidence on clinical utility 
49 Exner et al. 2014[137] Decision impact study no outcomes on clinical utility 
50 Segui et al. 2014[138] Related to cost effectiveness 
51  Yin et al. 2014[139] concordance study 
52 Zanotti et al. 2014[140] Review  
53 Krop et al. 2017[41] Guideline publication/consensus meeting 
54 Kuijer et al. 2016[107] Decision impact study no outcomes on clinical utility 
55 Beumer et al. 2016[102] Technical and/or clinical validation (duplicate with 11) 
56 Delahaye et al. 2017[141] Technical and/or clinical validation 
57 Kuijer et al. 2017[142] Decision impact study no outcomes on clinical utility 
58 Esserman et al. 2017[143] Technical and/or clinical validation 
59 Curigliano et al. 2017[39] Guideline- publication/consensus meeting  
60 Straver et al. 2010[144] neo-adjuvant setting 
61 Knauer et al. 2010[145] Decision impact study direct evidence on clinical utility 
62 Glück et al. 2013[146] neo-adjuvant setting 
63 Groenendijk et al. 2013[147] concordance study  
64 Krijgsman et al. 2012[148] concordance study in neo-adjuvant setting 
65 Whitworth et al. 2014[149] neo-adjuvant setting 
66 Retel et al. 2013[13] No supportive evidence on clinical utility 
 
 
 
Table A 7: Reason enrolment was not successful (screening failure) 
Reason for screening failure 
 
All screening 
failures (n=4595) 
n(%) 
MammaPrint® not feasible (mostly 
<50%/<30% tumour cells) 
1182 (26%) 
Patient/investigator decision 899 (20%) 
Ineligible: LN status 772 (17%) 
Inadequate/absent sample 768 (17%) 
Ineligible: other 447 (10%) 
Unknown or other 527 (11%) 
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Table A 8. List of relevant on-going studies with gene-expression signature 
Study identifier Estimated 
completion 
date 
Study 
type 
Number 
of 
patients 
Intervention Compa
rator 
Patient population Endpoints 
NCT00310180 
(TAILORx) 
31 December 
2017 
RCT 11248 No chemotherapy 
based on 
Oncotype DX® 
Chemoth
erapy 
Breast cancer patients with 
node-negative, estrogen-
receptor positive breast 
cancer by using a special 
test (Oncotype DX®), and 
whether hormone therapy 
alone or hormone therapy 
together with combination 
chemotherapy is better for 
women who have an 
Oncotype DX® recurrence 
score of 11-25. 
To determine whether adjuvant hormonal 
therapy is not inferior to adjuvant 
chemohormonal in women whose tumours 
meet established clinical guidelines for 
adjuvant chemotherapy and fall in the 
"primary study group" category (Oncotype 
DX® Recurrence Score 11-25).  
•Distant recurrence-free interval 
•Overall survival 
•Recurrence-free interval 
•Perceived cognitive function evaluated using 
the Functional Assessment of Cancer Therapy 
- Cognitive Function 
•Quality of life measured using FACT-COG, 
fatigue (FACT-Fatigue and Patient Reported 
Outcomes Measurement Information System 
Fatigue SF), fear of recurrence (Assessment 
of Survivor Concerns), endocrine symptoms 
(FACT-ES) and HRQL (FACT-General) [time 
frame: up to 36 months ] 
NCT01272037 
RxPONDER 
1 February 
2022 
RCT 10000 No chemotherapy 
based on 
Oncotype DX®. 
Chemoth
erapy  
A Phase III, randomized 
clinical trial of standard 
adjuvant endocrine therapy 
+/- chemotherapy in 
patients With 1-3 positive 
To determine the effect of chemotherapy in 
patients with node-positive breast cancer 
who do not have high recurrence scores (RS) 
by Oncotype DX®. 
•Overall survival  
9.3.2 List of relevant on-going and planned studies 
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nodes, hormone receptor-
positive and HER2-negative 
breast cancer with 
Recurrence Score (RS) of 25 
or Less. RxPONDER: A 
Clinical Trial Rx for Positive 
Node, Endocrine Responsive 
Breast Cancer 
•Distant disease-frees survival (DDFS)  
•Local disease-free interval (LDFI) 
•Toxicity 
•Patient-reported anxiety 
•Initial management cost of node-positive, 
hormone receptor-positive, HER2-negative 
breast cancer. 
•Patient-reported utilities (e.g., quality of 
life) for those randomised to chemotherapy 
versus no chemotherapy. 
Source: clinicaltrials.gov 
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9.3.3 Risk of bias tables 
 
Table A 9. Risk of bias – study level (RCTs) 
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MINDACT 
CH/GL 
Yes Yes No1 No1 Yes No2 High3 
MINDACT 
CL/GH 
Yes Yes No1 No1 Yes Yes Low4 
Abbreviations: CH/GL: clinical high and genomic low, CL/GH = clinical low and genomic high; PP: per 
protocol; OS overall survival; DMFS: distant metastasis-free survival; DFS: disease-free survival.  
Source: MINDACT 
1 Open-label study  
2 Of the patients randomised to chemotherapy (n=749) 174 (23%) patients were not included in the PP 
analysis (of whom 128 did not receive chemotherapy and 26 had a change of risk). Of those assigned to 
no chemotherapy (n=748), 119 (16%) were not included in the PP analysis (of whom 85 received 
chemotherapy and 21 had a change of risk). No lost to follow up data is mentioned. Because a 
considerable number of patients could not be analysed in the PP analysis, it is not clear if the baseline 
characteristics were still comparable or there was selective dropout. The results do not show if both groups 
are comparable.  
3 Because of both 1 and 2 it is concluded that risk of bias is high.  
4 We have rated the risk of bias as low because in the case of OS, DFS, and DMFS, we find downgrading 
only for the fact that study was open-label too strict. 
 
 
 
Table A 10. Risk of bias – outcome level (RCTs) 
Outcome 
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Outcome 
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High* Low Low Low Low 
DFS 5y      
MINDACT 
(CH/GL) 
High* High (PP)# Low Low High 
MINDACT 
(CL/GH) 
High* Low Low Low Low 
      
QoL      
MINDACT 
(CH/GL) 
Not 
performed¥ 
    
MINDACT 
(CL/GH) 
Not 
performed¥ 
    
      
Side effects of 
chemotherapy 
     
MINDACT 
(CH/GL) 
Not 
reported 
    
MINDACT 
(CL/GH) 
Not 
reported 
    
      
Abbreviations: CH/GL: clinical high and genomic low, CL/GH = clinical low and genomic high; ITT: 
intention to treat; OS overall survival; DMFS: distant metastasis-free survival; DFS: disease-free survival; 
QoL: quality of life. 
Source: MINDACT 
* Because outcome assessor was not blinded there is a risk of bias because there is some degree of 
subjectivity in assessing DMFS and DFS  
# PP analysis is used. Because a considerable amount of patients couldn’t be analysed in the PP population 
it is not sure if the baseline characteristics were still comparable or selective drop out is the case. 
 ¥ QoL was measured by Retel et al. [13] in 347 (566 enrolled) patients of the MINDACT. The primary 
aims of the study were to evaluate the association between breast cancer patients’ well-being and the 
results of a gene expression profile on to compare different recurrence risk groups, according to their 
genomic and standard clinical risk assessment. Different questionnaires were taken to assess the QoL. The 
QoL was assessed 6-8 weeks after surgery. This study does not compare QoL in the long term between 
CH/GL patients receiving treatment based on the MammaPrint® result and receiving treatment based on 
the AO! [13]. 
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Table A 11. GRADE assessment; population with a CH/GL risk (PPS) 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Adjuvant! 
Online and 
MammaPrint® 
Only 
Adjuvant! 
Online 
Relative 
(95% 
CI) 
Absolute 
(95% 
CI) 
Overall survival after 10 years (follow up: median 5 years; assessed with: surrogate OS 5 year) 
1  Randomised 
trials  
Not 
serious 
a 
Not serious b Serious c Very serious 
d 
None  525/542 
(96.9%) * 
495/503 
(98.4%)* 
HR 0.54 
(0.23 to 
1.26)  
91 
fewer 
per 
1.000 
(from 10 
more to 
370 
fewer)  
⨁◯◯◯ 
VERY 
LOW  
CRUCIAL  
Overall survival after 10 years (follow up: median 5 years; assessed with: surrogate DMFS 5y) 
1  Randomised 
trials  
Not 
serious 
e 
Not serious b Serious e Serious e None  509/542 
(93.9%)* 
485/503 
(96.4%)* 
HR 0.60 
(0.34 to 
1. 06)  
100 
fewer 
per 
1.000 
(from 6 
more to 
287 
fewer)  
⨁⨁◯◯ 
LOW  
CRUCIAL  
Overall survival after 10 years (follow up: median 5 years; assessed with: DFS 5y) 
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Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Adjuvant! 
Online and 
MammaPrint® 
Only 
Adjuvant! 
Online 
Relative 
(95% 
CI) 
Absolute 
(95% 
CI) 
1  Randomised 
trials  
Serious 
f 
Not serious b Serious f Serious f None  481/542 
(88.7%)* 
471/503 
(93.6%)* 
HR 0.57 
(0.37 to 
0.87)  
144 
fewer 
per 
1.000 
(from 27 
fewer to 
297 
fewer) 
⨁⨁◯◯ 
LOW  
CRUCIAL  
Quality of life - not measuredg 
-  -  -  -  -  -  -   -  CRUCIAL  
Short-term and long-term side effects from chemo - not reported 
-  -  -  -  -  -  -   -  CRUCIAL  
Abbreviations: CI: Confidence interval; HR: Hazard Ratio 
a We did not downgrade separately for risk of bias, although there is a risk of attrition bias. Of the patients randomised to chemotherapy (n=749) ,174 (23%) patients were not 
included in the PP analysis (of whom 128 did not receive chemotherapy and 26 had a change of risk). Of those assigned to no chemotherapy (n=748), 119 (16%) were not 
included in the PP analysis (of whom 85 received chemotherapy and 21 had a change of risk). No lost to follow up data is mentioned. Because a considerable number of 
patients could not be analysed in the PP analysis, it is not clear if the baseline characteristics were still comparable or there was selective dropout. The results do not show if 
both groups are comparable. Furthermore, patients, caregivers, and assessors were not blinded, but we did not deem it necessary to downgrade because OS is an objective 
outcome measure. Overall, we find it too strict to downgrade again.  
b There is only one publication so inconsistency is not possible.  
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c Because ten-year follow-up is essential, we have downgraded because only five-year data is available.  
d Using the thresholds of clinical relevance of the ESMO (ESMO-MCBS) (HR<0.65 or <0.65 HR <0.80), the 95% CI crosses the thresholds at both sides (independent if you 
make use of the threshold of 0.65 or 0.80). That is the reason for downgrading twice. 
e In total, we have downgraded twice because of: risk of bias (attrition bias and detection bias), indirectness (the relation between 5-year DMFS and 10-year OS is not 
validated. If the standard care AO! is not used in your country, you should consider downgrading an extra time for indirectness), and imprecision (using the ESMO-MCBS 
criteria, the lower boundary of 95% CI crosses line of clinical relevance (see Figure A2). 
f In total we have downgraded twice because of: risk of bias (attrition bias and detection bias), indirectness the relation between 5-year DMFS and 10-year OS is not validated. 
If the standard care AO! is not used in your country, you should consider downgrading an extra time for indirectness), and imprecision (using the ESMO-MCBS criteria, the 
lower boundary of 95% CI crosses line of clinical relevance (see Figure A2)). 
g QoL was measured by Retel et al. [13] in 347 (566 enrolled) patients of the MINDACT. The primary aims of the study were to evaluate the association between breast cancer 
patients’ well-being and the results of a gene expression profile on to compare different recurrence risk groups, according to their genomic and standard clinical risk 
assessment. Different questionnaires were taken to assess the QoL. The QoL was assessed 6-8 weeks after surgery. This study does not compare QoL in the long term between 
CH/GL patients receiving treatment based on the MammaPrint® result and receiving treatment based on the AO! [13]. 
* Our calculations differ a little from the published numbers. The calculation for five-year survival percentage takes into account the time at risk for each individual in the group 
up to 5 years. So, that includes the time at risk for each patient either with event (event time cut-off), or without event (censoring time cut-off). This is probably the reason 
why the percentages in the GRADE table differ a little from the percentages in the MINDACT publication.  
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Figure A 2. PPS-analysis: HR of OS, DMFS and DFS with 95% CI.  
 
 
Abbreviations: DFS: disease-free survival; DMFS: distant metastasis-free survival; HR: hazard ratio; OS: overall survival. 
*1 = thresholds for clinical relevance. 
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Table A 12. GRADE assessment; population with a CL/GH risk (ITT) 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Adjuvant! 
Online and 
MammaPrint® 
Only 
Adjuvant! 
Online 
Relative 
(95% 
CI) 
Absolute 
(95% 
CI) 
Overall survival after 10 years (follow up: median 5 years; assessed with: OS 5 year) 
1  Randomised 
trials  
Not 
serious 
a 
Not serious b Serious c,d Very serious 
e 
None  333/344 
(96.8%) * 
336/346 
(97.1%) * 
HR 
1.28# 
(0.54 to 
3.02)  
18 more 
per 
1.000 
(from 29 
more to 
119 
fewer)  
⨁◯◯◯ 
VERY 
LOW  
CRUCIAL  
Overall survival after 10 years (follow up: median 5 years; assessed with: DMFS 5y) 
1  Randomised 
trials  
Not 
serious 
a 
Not serious b Serious d,f Very serious 
e 
None  326/344 
(94.8%) *  
329/346 
(95.1%) *  
HR 
1.17# 
(0.59 to 
2.28)  
20 more 
per 
1.000 
(from 48 
more to 
120 
fewer)  
⨁◯◯◯ 
VERY 
LOW  
CRUCIAL  
Overall survival after 10 years (follow up: median 5 years; assessed with: DFS 5y) 
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Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Adjuvant! 
Online and 
MammaPrint® 
Only 
Adjuvant! 
Online 
Relative 
(95% 
CI) 
Absolute 
(95% 
CI) 
1  Randomised 
trials  
Not 
serious 
a 
Not serious b Serious d,g Very serious 
e 
None  316/344 
(91.9%) * 
312/346 
(90.2%) * 
HR 
0.87# 
(0.53 to 
1.45)  
35 
fewer 
per 
1.000 
(from 64 
more to 
194 
fewer) 
⨁◯◯◯ 
VERY 
LOW  
CRUCIAL  
Quality of life - not measured** 
-  -  -  -  -  -  -   -  CRUCIAL  
Short-term and long-term side effects from chemo - not reported 
-  -  -  -  -  -  -   -  CRUCIAL  
Abbreviations: CI: Confidence interval; HR: hazard ratio. 
a We did not downgrade. There is some risk of bias because the patients, caregivers and assessors were not blinded. For OS, DMFS, and DFS, this will not make a difference if 
patients and caregivers were blinded or not. However, it may influence the assessor in his opinion if there is a metastasis of other form of progression. We find it too strict to 
downgrade for risk of bias.  
b There is only one publication so inconsistency is not possible  
c Because ten-year follow-up is essential, we have downgraded because only five-year data is available. 
d We did not downgrade for the standard care (Adjuvant! Online) because in Belgium and the Netherlands this is according to clinical guidelines. If this standard is very different 
in other countries, you should consider downgrading an extra time for indirectness.  
e Using the thresholds of clinical relevance of the ESMO (ESMO-MCBS) (HR<0.65 or <0.65 HR <0.80), the 95% CI crosses the thresholds at both sides (independent if you 
MammaPrint® for early breast cancer 
 
    
 
Version 1.3 December 2017                              EUnetHTA JA3 WP4                                                    
90                                                                                                                                                                                                                 
  
make use of the threshold of 0.65 or 0.80). That is the reason why it is downgraded twice.  
f We have downgraded once because the relation between 5-year DMFS and-10 year OS is not validated.  
g We've downgraded because the relation between 5-year DFS and 10-year OS is not validated.  
* Our calculations differ a little from the published numbers. . The calculation for five-year survival percentage takes into account the time at risk for each individual in the 
group up to 5 years. So, that includes the time at risk for each patient either with event (event time cut-off), or without event (censoring time cut-off). This is probably the 
reason why the percentages in the GRADE table differ a little from the percentages in the MINDACT publication. 
# The HRs do not correspond with the survival data (DFS and OS), possibly because the curves are crossing.  
** QoL was measured by Retel [13] et al. in 347 (566 enrolled) patients of the MINDACT. The primary aims of the study were to evaluate the association between breast 
cancer patients’ well-being and the results of a gene expression profile on to compare different recurrence risk groups, according to their genomic and standard clinical risk 
assessment. Different questionnaires were taken to assess the QoL. The QoL was assessed 6-8 weeks after surgery. This study does not compare QoL in the long term between 
CH/GL patients receiving treatment based on the MammaPrint® result and receiving treatment based on the AO! [13].  
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Figure A 3. ITT analysis: HR of OS, DMFS and DFS with 95% CI.  
 
 
Abbreviations: DFS: disease-free survival; DMFS: distant metastasis-free survival; HR: hazard ratio; OS: overall survival. 
*1 = thresholds for clinical relevance. 
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9.3.4 Applicability tables 
 
Table A 13. Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The majority of enrolled patients are patients with ER-positive and 
HER2-negative tumours. These patients with ER-positive and HER2-
negative tumours are relevant to the target population of early breast 
cancer patients: in particular in the subset of patients with ER positive 
and HER2-negative tumours in which there is controversy regarding the 
benefit of adjuvant chemotherapy, and hence controversy on decisions 
on adjuvant chemotherapy. 
 
Intervention MammaPrint® is a genomic expression signature test: see considerations 
described in the ‘Population’, ‘Comparators’ and ‘Outcomes’ domain. 
 
Comparators The comparator in the MINDACT study is Adjuvant! Online. Although 
Adjuvant! Online has been globally investigated in validation studies, 
some concerns have been raised regarding their applicability in 
populations other than those used in their validation studies. Currently 
Adjuvant! Online is being updated. An update potentially can lead to 
impact on the baseline risks of recurrence and hence this may 
potentially limit the clinical applicability of the MINDACT results. 
 
Outcomes Wide confidence intervals were found for all surrogate outcome 
measures. The confidence intervals show there is a lot of uncertainty 
and possibly many patients could be harmed in terms of hazards of 
death. 
 
Setting See considerations described in the ‘Comparators’ domain. 
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Table A 14. Outcome according to discordant risk group CH/GL and treatment strategy 
 
Risk group, Outcome, and 
treatment strategy 
Chemo- 
therapy 
No. of 
patients 
No. of events Percentage  
at 5 years (95% 
CI) 
Hazard ratio (95% 
CI) 
P 
value 
High clinical risk and low 
genomic risk (PPS) 
      
Overall survival (5y) (OS)       
• Using clinical risk Yes 503 8 98.8 (97.1-99.5) 0.57 (0.23 – 1.26) 0.154 
• Using genomic risk (add on) No 542 17 97.0 (94.9-98.2) 1.00  
       
Survival without distant 
metastasis 5y (DMFS) 
      
• Using clinical risk Yes 503 18 96.5 (94.1-97.9) 0.60 (0.34-1.06) 0.080 
• Using genomic risk (add on) No 542 33 94.0 (91.4-95.8) 1.00  
       
Disease-free survival 5y (DFS)       
• Using clinical risk Yes 503 32 93.3 (90.3-95.4) 0.57 (0.37-0.87) 0.009 
• Using genomic risk (add on) No 542 61 88.8 (85.7-91.3) 1.00  
High clinical risk and low 
genomic risk (PP) 
      
Overall survival (5y) (OS)       
• Using clinical risk Yes 592 10 98.8 (97.4-99.5) 0.63 (0.29 – 1.37) 0.25 
• Using genomic risk (add on) No 636 18 97.3 (95.6-98.4) 1.00  
       
Survival without distant 
metastasis 5y (DMFS) 
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• Using clinical risk Yes 592 22 96.7 (94.7-98.0) 0.65 (0.38-1.10) 0.11 
• Using genomic risk (add on) No 636 37 94.8 (92.6-96.3) 1.00  
       
Disease-free survival 5y (DFS)       
• Using clinical risk Yes 592 39 93.3 (90.7-95.2) 0.64 (0.43-0.95) 0.03 
• Using genomic risk (add on) No 636 66 90.3 (87.6-92.4) 1.00  
High clinical risk and low 
genomic risk (ITT) 
      
Overall survival (5y) (OS)       
• Using clinical risk Yes 749 14 98.4 (97.0-99.1) 0.69 (0.35-1.35) 0.278 
• Using genomic risk (add on) No 748 22 97.0 (95.4-98.1) 1.00  
       
Survival without distant 
metastasis 5y (DMFS) 
      
• Using clinical risk Yes 749 34 95.9 (94.0-97.2) 0.78 (0.50-1.21) 0.267 
• Using genomic risk (add on) No 748 46 94.4 (92.3-95.9) 1.00  
       
Disease-free survival 5y (DFS)       
• Using clinical risk Yes 749 54 92.9 (90.5-94.7) 0.71 (0.50-1.01) 0.055 
• Using genomic risk (add on) No 748 78 90.1 (87.5-92.1) 1.00  
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Table A 15. Outcome according to discordant risk group CL/GH and treatment strategy 
 
Risk group, Outcome, and 
treatment strategy 
Chemoth
erapy 
No. of 
patients 
No. of 
events 
Percentage with 
outcome at 5 years 
(95% CI) 
Hazard ratio 
(95% CI) 
P value 
Low clinical risk and high 
genomic risk (ITT) 
      
Survival without distant 
metastasis 5y (DMFS) 
      
• Using genomic risk (add on) Yes 344 18 95.8 (92.9-97.6) 1.17* (0.59-
2.28) 0.657 
• Using clinical risk No 346 17 95.0 (91.8-97.0) 1.00 
       
Disease-free survival 5y (DFS)       
• Using genomic risk (add on) Yes 344 28 92.1 (88.3-94.6) 0.87* (0.53-
1.45) 
0.603 
• Using clinical risk No 346 34 90.1 (86.1-93.0) 1.00  
       
Overall survival (5y) (OS)       
• Using genomic risk (add on) Yes 344 11 97.1 (94.5-98.5) 1.28* (0.54-
3.02) 
0.578 
• Using clinical risk No 346 10 97.8 (95.5-99.0) 1.00  
* In the case of DFS and OS, the HR does not correspond with the percentage outcome after five years, a possible explanation being that the curves of the MammaPrint® and 
AO! groups cross each other. The HRs published in MINDACT are adjusted, but it is not clear if they are adjusted for these crossings. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304842/ 
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Table A 16. Outcome according for different pre-specified subgroups and treatment strategy 
 
Risk group, Outcome, and treatment 
strategy 
Chemoth
erapy 
No. of 
patients 
No. of events Percentage with outcome 
at 5 year (95% CI) 
Adjusted Hazard 
ratio (95% CI) 
P value 
High genomic risk (clinical high 
and clinical low) 
 2398     
Survival without distant metastasis 5y  
(DMFS) using only genomic risk 
   94.7*    
       
High clinical risk (genomic high 
and genomic low) 
 3356     
Survival without distant metastasis 5y  
(DMFS) using only clinical risk 
   95.0*   
       
Cordant groups       
High clinical risk and high genomic 
risk 
Yes 1806     
OS 5Y   103 94.7 (93.4–95.7)   
DMFS   171 90.6 (89.0-92.0)   
DFS   266 85.3 (83.4-87.0)   
       
Low clinical risk and low genomic 
risk 
No 2745     
OS 5Y   47 98.4 (97.8–98.9)   
DMFS   77 97.6 (96.9-98.1)   
DFS   211 92.8 (91.7-93.7)   
       
Subgroup: by nodal status (ITT1 
population) 
      
Clinical high/genomic low LN0       
DMFS       
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Using clinical risk Yes 395  95.7 (93.0-97.4) 0.69 (0.39-1.21) 0.19 
Using genomic risk (add on) No 392  93.2 (90.1-95.4) 1.00  
       
Clinical high/genomic low N+       
DMFS       
Using clinical risk Yes 353  96.3 (93.1-98.1) 0.88 (0.42-1.82) 0.72 
Using genomic risk (add on) No 356  95.6 (92.7-97.4) 1.00  
       
Clinical low/genomic high LN0        
DMFS       
Using clinical risk No 333  95.1 (91.9-97.1) 1.00 0.82 
Using genomic risk (add on) Yes 333  96.0 (93.1-97.7) 1.09 (0.54-2.19)  
       
Clinical low/genomic high N+       
DMFS  Group too 
small to 
be 
analysed 
    
       
Subgroup: by tumour size (ITT1 
population) 
      
Clinical high/genomic low T2       
DMFS       
Using clinical risk Yes 402  94.5 (91.4-96.6) 0.90 (0.53-1.54) 0.71 
Using genomic risk (add on) No 406  93.7 (90.6-95.8) 1.00  
       
Clinical high/genomic low T1       
DMFS       
Using clinical risk Yes 322  97.6 (95.1-98.9) 0.59 (0.26-1.33) 0.20 
Using genomic risk (add on) No 314  94.8 (91.5-96.8) 1.00  
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Clinical low/genomic high T1       
DMFS       
Using clinical risk No 338  94.9 (91.6-96.9) 1.00 0.85 
Using genomic risk (add on) Yes 333  95.7 (92.6-97.5) 1.07 (0.54-2.12)  
       
Clinical low/genomic high 
T2 
      
DMFS  Group too 
small to 
be 
analysed 
    
       
Subgroup: HR-/+/HER2-/+/LN0 
(ITT1 population) 
      
Clinical high/genomic low  
HR+/HER2-/LN0 
      
DMFS       
Using clinical risk Yes 349  95.5 (92.5-97.3) 0.80 (0.44-1.45) 0.46 
Using genomic risk (add on) No 350  93.9 (90.6-96.1) 1.00  
       
Clinical low/genomic high HR-
/HER2+/LN0 
      
DMFS       
Using clinical risk No 262  95.5 (91.6-97.6) 1.00 0.33 
Using genomic risk (add on) Yes 272  95.1 (91.5-97.2) 1.45 (0.68-3.08)  
* To have an unbiased estimate, the discordant patients are doubly weighted, because they are underrepresented by a factor of two in the resulting sample. Therefore, 
comparison by means of classical statistical inference is incorrect and only the estimates of the five-year DMFS are shown.  
  
10  APPENDIX 2: CHECKLIST FOR POTENTIAL ETHICAL, 
ORGANISATIONAL, PATIENT, SOCIAL AND LEGAL ASPECTS 
1. Ethical  
1.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) 
give rise to any new ethical issues? 
Yes 
Introduction of MammaPrint® at this moment (with only the availability of five-year data 
with wide CI’s and therefore a lot of uncertainty) can lead to some ethical issues both for 
the patient as well as for the healthcare provider. For the patient, there is the ethical issue 
of a trade-of between survival benefit versus deterioration in quality of life. For the 
healthcare provider, the ethical issue is: how to comply with the principle of clinical utility, 
in this case accepting a potential aggressive treatment without expecting health benefit 
versus how to comply with the principle to adhere to patient autonomy and shared 
decision-making.  
1.2. Does comparing the new technology to the defined, existing 
comparators point to any differences that may be ethically 
relevant? 
Yes 
See 1.1. 
The current data does not point to a statistical difference between chemotherapy following 
clinical high-risk assignment and no chemotherapy following MammaPrint® low-risk 
assignment in the primary endpoint of DMFS. However, it cannot be concluded that 
MammaPrint® is non-inferior because the 95% CI of five-year DMFS and 5-year DFS are 
crossing the non-inferiority threshold. Only when the entire 95% CI is above the non-
inferiority threshold it can be concluded that MammaPrint® is non-inferior compared with 
AO!. As pointed out in the results and discussion, it cannot be excluded that adjuvant 
chemotherapy following the clinical risk assignment significantly decreases the hazard of 
death due to distant metastasis. So, when MammaPrint® is introduced prematurely, 
omitting chemotherapy following genomic risk assignment may place patients at increased 
risk of premature death due to metastatic disease which could have been prevented by 
adjuvant chemotherapy.  
2. Organisational 
 
2.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) 
require organisational changes? 
No 
 
2.2. Does comparing the new technology to the defined, existing 
comparator(s) point to any differences that may be 
organisationally relevant? 
No 
 
3. Social 
 
3.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) 
give rise to any new social issues? 
Yes 
Yes, if a patient can safely omit chemotherapy she will probably be able to keep working 
as normal. On the other side, more deaths can possibly be expected.  
  
3.2. Does comparing the new technology to the defined, existing 
comparator(s) point to any differences that may be socially 
relevant? 
Yes 
 See 3.1 
4. Legal  
 
4.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) 
give rise to any legal issues? 
No 
 
4.2. Does comparing the new technology to the defined, existing 
comparator(s) point to any differences that may be legally 
relevant? 
No 
 
 
A separate appendix with comments from external experts and the 
MAH/manufacturer(s), as well as responses from authors, for the purposes of 
transparency, is published separately. 
 
 
 
 
 
